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Abstract
Sudden cardiac arrest is a leading cause of death and disability in the US, with over 500,000 events
annually and <20% surviving to hospital discharge. Half of survivors suffer some degree of neurologic
disability from massive ischemic injury and subsequent reperfusion processes. It therefore is vital to
evaluate cardiac arrest at both population and clinical levels to improve outcomes. In response, this
dissertation had three objectives. First, we examined whether hospital performance could be
benchmarked using administrative data, which is more common than registry data. Two risk
standardization models were developed using logistic regression involving 2453 patients treated from
2000-2015 at University of Pennsylvania Health System hospitals. Registry and administrative data were
accessed for all patients and used to develop separate risk standardization models with survival to
hospital discharge as the outcome and the registry model considered the “gold standard.” The
administrative model had a receiver operating characteristic (ROC) area of 0.891 (95% CI: 0.876-0.905)
compared to a registry area of 0.907 (95% CI: 0.895-0.919), indicating that risk standardization can be
performed using administrative data. Second, serial temperatures were collected during the 72 hours
following targeted temperature management (TTM) and rewarming on 465 TTM-treated patients from the
Penn Alliance for Therapeutic Hypothermia (PATH) registry, of whom 179 (38.5%) had at least one pyrexic
temperature (≥38oC). Higher maximum temperature was associated with worse neurologic outcome and
lower survival in pyrexic patients. Pyrexia duration and outcomes were not related, unless duration was
calculated as hours at or above 38.8oC; at those elevated temperatures, longer duration was associated
with worse neurologic and survival outcomes. Third, serial temperatures were collected during the 72
hours post-arrest on 578 PATH patients not treated with TTM; 228 (39.5%) had at least one pyrexic
temperature. Worse neurologic and survival outcomes were associated with increasing maximum
temperature, the combination of higher maximum temperatures and longer durations at an elevated
temperature, and timing of onset of pyrexia between 10.2-24.5 hours post-arrest. This work establishes
the potential for using administrative data to create new opportunities to compare hospital performance
regarding cardiac arrest and extends knowledge on clinical implications of post-arrest temperature on
outcomes.
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ABSTRACT

SUDDEN CARDIAC ARREST: NOVEL USES OF RISK STANDARDIZATION AND
POST-ARREST BODY TEMPERATURE TO IMPROVE OUTCOMES
Anne V. Grossestreuer, M.S.
Benjamin S. Abella, M.D., M.Phil.
Sudden cardiac arrest is a leading cause of death and disability in the US, with over
500,000 events annually and <20% surviving to hospital discharge. Half of survivors
suffer some degree of neurologic disability from massive ischemic injury and subsequent
reperfusion processes. It therefore is vital to evaluate cardiac arrest at both population and
clinical levels to improve outcomes. In response, this dissertation had three objectives.
First, we examined whether hospital performance could be benchmarked using
administrative data, which is more common than registry data. Two risk standardization
models were developed using logistic regression involving 2453 patients treated from
2000-2015 at University of Pennsylvania Health System hospitals. Registry and
administrative data were accessed for all patients and used to develop separate risk
standardization models with death prior to hospital discharge as the outcome. The
registry model considered the “gold standard.” The administrative model had a receiver
operating characteristic (ROC) area of 0.891 (95% CI: 0.876-0.905) compared to a
registry area of 0.907 (95% CI: 0.895-0.919), indicating that risk standardization can be
performed using administrative data. Second, serial temperatures were collected during
72 hours following targeted temperature management (TTM) and rewarming on 465
TTM-treated patients from the Penn Alliance for Therapeutic Hypothermia (PATH)
iv

registry, of whom 179 (38.5%) had at least one pyrexic temperature (≥38C). Higher
maximum temperature was associated with worse neurologic outcome and lower survival
in pyrexic patients. Pyrexia duration and outcomes were not related, unless duration was
calculated as hours ≥38.8C; at those elevated temperatures, longer duration was
associated with worse neurologic and survival outcomes. Third, serial temperatures were
collected during the 72 hours post-arrest on 578 PATH patients not treated with TTM;
228 (39.5%) had at least one pyrexic temperature. Worse neurologic and survival
outcomes were associated with increasing maximum temperature, the combination of
higher maximum temperatures and longer durations at an elevated temperature, and
timing of onset of pyrexia between 10.2-24.5 hours post-arrest. This work establishes the
potential for using administrative data to create new opportunities to compare hospital
performance regarding cardiac arrest and extends knowledge on clinical implications of
post-arrest temperature on outcomes.
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CHAPTER 1
Cardiac arrest risk standardization using administrative data compared to registry
data

INTRODUCTION
Cardiac arrest is a challenge to prevent, manage, and study as a clinical condition
in the real world. Differences in definitions (Nishiyama et al. 2014), termination-ofresuscitation rules (Sasson et al. 2009; Sasson et al. 2010), data collection (Cummins et
al. 1991; Jacobs et al. 2004; Nishiyama et al. 2014) and participation in registries (Sasson
et al. 2010), as well as patient heterogeneity (Cabanas et al. 2015) make even capturing
the incidence of sudden cardiac arrest difficult (Cummins et al. 1991; Grasner et al. 2011;
Jacobs et al. 2004; Morrison et al. 2008; Nishiyama et al. 2014). This diversity can lead
to differences in outcomes that may be influenced by variations in care (Carr et al. 2009a;
Carr et al. 2009b; Chen et al. 2015; Fredriksson, Herlitz, Nichol 2003; Heffner et al.
2012; Hinchey et al. 2010; Kellum, Kennedy, Ewy 2006; Kellum et al. 2008; LundKordahl et al. 2010; Nichol et al. 2008; Nichol and Soar 2010; Spaite et al. 2014; Stub et
al. 2015). However, recent initiatives to change both intra- and post-arrest care have led
to improved outcomes (Adielsson et al. 2011; Fothergill et al. 2013; Fugate et al. 2012;
Hollenberg, Svensson, Rosenqvist 2013; Iwami et al. 2009; Iwami et al. 2012; Japanese
Circulation Society Resuscitation Science Study Group 2013; Kitamura et al. 2010;
Kitamura et al. 2012; Neumar et al. 2008; Peberdy et al. 2010; Ro et al. 2013; Tagami et
al. 2012; Weisfeldt et al. 2010; Wissenberg et al. 2013), highlighting the importance of
performing these assessments. Additionally, the Institute of Medicine has recognized as a
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priority the need for better cardiac arrest data collection and outcomes improvement
(Becker, Aufderheide, Graham 2015).
An important step to better understand the management of cardiac arrest involves
comparing hospitals to determine which modalities and clinical protocols are associated
with better outcomes (Donnino et al. 2012). Unfortunately, many US hospitals do not
participate in a registry that provides such outcomes; contributing can be prohibitive in
terms of financial and time costs (Khuri et al. 1998; Render et al. 2003). Additionally,
voluntary participation in a registry may lead to selection bias (Ferreira-Gonzalez et al.
2009). As registry data are the only current method for risk adjustment (Chan et al. 2013)
in cardiac arrest, there is no way to enable fair comparison of observed mortality relative
to expected mortality given patient characteristics across all US hospitals treating cardiac
arrest.
To our knowledge, no studies have investigated whether administrative data on
cardiac arrest, which have been shown to be effective in sepsis patients (Lagu et al.
2011). Administrative data potentially are available for all hospitals in the U.S., could
perform as well as registry data to accomplish risk standardization in order to study
variability in cardiac arrest outcomes. If, as we hypothesized, administrative-type data
perform as well as registry data in this population, we will have evidence that a tool for
risk standardization can be developed and applied to hospitals across the US. Using data
from a national cardiac arrest registry at the University of Pennsylvania and
administrative data from the University of Pennsylvania Health System on the same
cohort of cardiac arrest patients, we aimed to develop a method for risk-standardizing
hospital survival after cardiac arrest using administrative data that is validated against one
2

using registry data.

METHODS
Data source
The registry data were from the Penn Alliance for Therapeutic Hypothermia
(PATH) database. PATH is an internet-based registry established by the University of
Pennsylvania in 2010. PATH includes cardiac arrest data from pre-hospital, emergency
department, and in-hospital settings. Potentially available to any US hospital, PATH
supports the tracking of all patients who experience cardiac arrest and receive
cardiopulmonary resuscitation. Cardiac arrest is defined in PATH as a loss of pulse with
subsequent chest compressions. Each patient record in PATH consists of 30 required data
elements based on the Utstein template (Jacobs et al. 2004; Perkins et al. 2014). One
hundred additional data elements are required for research participation. Further optional
data elements are also available to address specific research questions. Data are entered
via a secure website and maintained on a password-protected encrypted server at the
University of Pennsylvania. Data are collected retrospectively at each of the participating
institutions. Before entering data, data abstractors undergo structured training including
mock case entry and case review. All participants are provided with a standardized data
dictionary and are subject to a formal auditing process (Leary et al. 2013). PATH
currently supports 34 member hospitals from 19 US states and includes data from over
5000 cardiac arrests. Exclusion criteria are age <18 years, traumatic etiology of arrest,
active do-not-resuscitate orders prior to arrest, and lack of administrative data. This study
was approved by the University of Pennsylvania Institutional Review Board.
3

Administrative data for this study were from the Penn Data Store, a research
initiative at the University of Pennsylvania that integrates clinical data on all University
of Pennsylvania Health System (UPHS) patients. All available administrative information
on cardiac arrest patients (defined as having an ICD-9 code of 427.5) seen at three UPHS
hospitals, the Hospital of the University of Pennsylvania, Penn Presbyterian Medical
Center, and Pennsylvania Hospital, was queried, and consisted of demographics,
procedure codes, diagnosis codes, and drug and other orders. These data were then
matched on medical record number to records from the PATH database. Only the patients
who have both registry data in PATH and administrative-type data in Penn Data Store
were included in the risk standardization model building.
Model building
Recommended guidelines for conducting risk adjustment for trauma, another
time-sensitive critical illness, have been published, allowing comparison of trauma center
outcomes (Newgard et al. 2013). Using these methods as guidance, we applied and
adapted that approach to develop two risk standardization models.
First, we developed a method for risk-standardization using registry data for inand out-of-hospital cardiac arrest patients using logistic regression with survival to
discharge as the outcome. Cox regression was not used because our interest was not in
time to the outcome of interest (death) but in whether death had occurred by hospital
discharge. A total of 17 variables (Table 1) were modeled as potential independent,
adjustor variables. The variables were selected to match, to the extent possible, the
variables in the Utstein template (Jacobs et al. 2004; Perkins et al. 2014). These variables
were modeled through a backward stepwise variable selection process (using a p<0.25 to
4

enter the model) (Maldonado and Greenland 1993; Mickey and Greenland 1989) to
generate the most parsimonious model and evaluate changes in predictive ability.
Variables that did not contribute to prediction were excluded from the final model. The
final model included race, whether the arrest was witnessed, initial rhythm, age, if intraarrest epinephrine was given, cumulative dose of intra-arrest epinephrine, if patient was
treated with TTM, year of arrest, and whether the patient regained consciousness shortly
post-arrest (defined as ineligibility for TTM due to purposeful following of commands).
Significant missing data (more than 5% but no more than 15%) were addressed through
multiple imputation, conducted using 20 iterations and then combined using the “mi
estimate” Stata command (Cañette and Marchenko 2013; Newgard et al. 2013; StataCorp
2013). A final logistic regression model generated the risk-adjusted predicted probability
of death for each patient, ranging from 0 to 1, with higher values indicating a higher
predicted probability that a given patient had died by hospital discharge. This final
predictive model was assessed using conventional techniques including the HosmerLemeshow goodness-of-fit statistic to assess calibration, calibration curves, c-statistic to
assess discrimination, and Akaike information criterion value to compare model fit and
composition across multiple models. The resulting model was considered the gold
standard for risk adjustment for our study purposes. In order to accommodate for multiple
imputation, we used two strategies once arriving at a final model to derive a predicted
probability for each patient: the predicted value of each of the imputed data sets averaged
per patient using the “mim” suite of commands (Galati, Royston, Carlin 2013) and by
using the imputed dataset closest to the median receiver operating characteristic (ROC)
curve with the better Hosmer-Lemeshow goodness-of-fit statistic.
5

To verify that there are not significantly better modeling methods of risk
standardization in this population, we repeated this analysis using hierarchical mixed
effect models and generalized estimating equations. Bayesian analysis was not explored,
due to its incompatibility with multiple imputation, and linear and Poisson regression
were not used because of the nature of the outcome and our question of interest
(dichotomous survival) (Newgard et al. 2013).
Next, we developed a method for risk-standardizing hospital survival using
administrative data. To identify candidate variables for exploration, we queried all
available diagnostic codes, procedure codes, demographics, and orders for all patients
with an ICD-9 code for cardiac arrest (427.5). We then isolated all unique diagnosis
codes, procedure codes, and orders. These were assessed by two physician-fellows in
resuscitation science to determine, by consensus, which of these should be explored as
candidate variables due to their possible relationship to survival. Each identified
candidate variable then was tested in univariate logistic regression against the outcome of
interest (death at hospital discharge).
We next employed the same logistic regression methodology to the administrative
data as was done with the registry data, developing a logistic regression model using
death at hospital discharge as the outcome. The administrative candidate variables were
modeled as potential independent, adjustor variables through a manual forward stepwise
variable selection process (using a univariate p<0.25 to enter the model) (Maldonado and
Greenland 1993; Mickey and Greenland 1989). Variables that did not contribute to
prediction were excluded from the final model. Variance inflation factors were checked
and collinear variables were collapsed or omitted. There was no missing data in the
6

administrative data set that was greater than 1%. The final logistic regression model
generated the risk-adjusted predicted probability of death for each patient; this model was
used in comparison to the “gold standard” registry model.
Finally, we assessed the performance of the risk standardization done using
administrative data to the performance of the “gold standard” risk standardization done
using registry data. The results for both sets of analysis were reported as c-statistics,
calibration plots, and Bland-Altman plots. To evaluate the models against each other, we
used Bland-Altman plots to assess mean difference in predicted values and the percentage
of values outside the limits of agreement, defined as two standard deviations of the mean
difference (Giavarina 2015), a Hosmer-Lemeshow plot of the performance of the
predicted values from each model compared to the observed values, and tests of the
equality of receiver operating characteristic (ROC) areas between models. The last
assessment, a test of the equality of ROC areas between models, was chosen a priori as
the final determination for model comparison, with significance assessed at p<0.05.
In the primary analysis, all patients will be included. However, due to differences
in out-of-hospital versus in-hospital cardiac arrest, the same methodology will be applied
to those two subgroups to evaluate differences in model performance based on location of
arrest.

RESULTS
Patient population
There were 2453 patients who had both administrative and registry data between
1/2000-4/2015. This cohort had a median age of 63 (IQR: 51, 74) years; 57.8% of these
7

patients were male, 44.1% white, 24.8% had an initial shockable rhythm of ventricular
fibrillation or pulseless ventricular tachycardia (VF/VT), 60.6% had a presumed cardiac
etiology of arrest, 53.7% had an out-of-hospital cardiac arrest (OHCA), 26.3% of OHCAs
received bystander CPR, 74.8% had a witnessed arrest, and 83.5% had intra-arrest
epinephrine given, with a median dose of 2 (IQR: 0, 3) mg. The median duration of arrest
was 11 (IQR: 5, 25) minutes, 62.5% had return of spontaneous circulation (ROSC),
19.8% of patients received TTM, 17.4% of patients regained arousal shortly post-ROSC,
25.8% of patients survived to hospital discharge, and 20.0% of patients had a favorable
neurologic outcome (as defined as a Cerebral Performance Category [CPC] score of 1-2,
an outcome measure which is commonly employed in the resuscitation literature
(Bernard et al. 2002; Hypothermia after Cardiac Arrest Study Group 2002; Nielsen et al.
2013; Perkins et al. 2014).
Registry risk standardization
There were 2622 cardiac arrests in PATH between 1/2000-4/2015 and 2453 of the
arrests matched with administrative data (93.6%). The patients that did not match with
administrative data were significantly more likely to have initial shockable rhythms, to be
African-American, to have a cardiac etiology of arrest, to have an OHCA, to have a
witnessed arrest, to not receive epinephrine intra-arrest and to receive a lower dose if
given, to have a longer duration of cardiac arrest, to achieve ROSC, to not receive TTM,
to regain consciousness shortly post-arrest, to survive to hospital discharge and to have an
CPC score of 1 or 2 at hospital discharge (Appendix Table 1).
The c-statistic in the final model containing nine predictor variables using the
average predicted values from each imputation was 0.9119 (95% CI: 0.9003-0.9235) with
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a median Hosmer-Lemeshow goodness-of-fit statistic of 0.36 (IQR: 0.19-0.58). The final
model using the median imputed dataset had a c-statistic of 0.9078 (95% CI: 0.89590.9197) with a Hosmer-Lemeshow goodness-of-fit statistic of 0.38. However, when
evaluating the risk standardization with Bland-Altman plots using the model composed of
the average predicted values from all imputations, we found a much worse fit in terms of
Pitman’s test of difference in variance than when using the single imputed dataset.
Therefore, we chose to use the values from the median imputed dataset as the “gold
standard”. The ROC area used for comparison to administrative modeling was slightly
different due to a few missing ages in the administrative dataset (<1%).
Use of generalized estimating equations controlling for clustering by year
provided identical results (c-statistic: 0.9078 [95% CI: 0. 0.8959-0.9197]). Use of a
mixed effects model with year as a random intercept resulted in an ROC area of 0.9147
(95% CI: 0.9028-0.9267), which was not statistically different from either the logistic
regression or the generalized estimating equations approach.
Administrative risk standardization
Penn Data Store reported 5424 patients between 1/2000-4/2015 with an ICD-9
code of 427.5. These patients were 57.3% male, 50.1% white, and had a median length of
hospital stay of 6 (IQR: 1, 17) days. Forty-five percent of the patients with an ICD-9 code
for cardiac arrest were matched with registry data. On these 5424 arrests, there were 1423
unique procedure codes, 2001 unique drugs, 5632 unique orders, and 4723 unique
diagnosis codes (13,792 candidate variables including race, sex, and age).
A list of all unique procedure codes, drug orders, other orders, and diagnosis
codes was compiled for assessment by two physician-fellows in resuscitation science
9

involved in this study. Both fellows eliminated any variables assessed as irrelevant for
predicting survival outcome in cardiac arrest patients. Any variable eliminated by one
fellow but not the other remained eligible for exploration. After the fellows’ assessment,
1719 (12.5%) potential variables remained. Each of these was then analyzed in univariate
logistic regression with survival to discharge as the outcome. Any variable with a p-value
of <0.25 remained eligible for the model, which resulted in 317 variables. Using manual
forward selection in order of lowest p-value to highest, variables were then entered into
the logistic regression model. Variables remained in the model if they improved the
predictive value and were removed if they worsened the predictive value or if it remained
the same. After analyzing all 317 variables, 133 remained in the model (Appendix Table
2) with a c-statistic of 0.8905 (95% CI: 0.8757-0.9054) and a Hosmer-Lemeshow
goodness of fit of 0.58. To get a c-statistic>0.80, only 15 variables were needed: codes
37.94 (Implantation or replacement of automatic cardioverter/defibrillator, total system),
96.72 (Continuous invasive mechanical ventilation for 96 consecutive hours or more),
96.04 (Insertion of endotracheal tube), 43.11 (Percutaneous [endoscopic] gastrostomy
[PEG]), 37.22 (Left heart cardiac catheterization), 414.01 (Coronary atherosclerosis of
native coronary artery), 507 (Pneumonitis due to solids and liquids), 599 (Urinary tract
infection, site not specified), 39.61 (Extracorporeal circulation auxiliary to open heart
surgery), 37.23 (Combined right and left heart cardiac catheterization), 427.41
(Ventricular fibrillation), 88.53 (Angiocardiography of left heart structures), year of
arrest, respiratory failure (composite of 518.81, 518.83, 518.84, and 799.1), and presence
of a DNR (composite of V49.86 and order for DNR-C [comfort measures]). The ROC
curve for this reduced model was 0.8004. To assess the performance of other models, we
10

used a generalized estimating equation model controlling for clustering by year and a
mixed effects model with year as a random intercept. Both of these models provided
identical results to the model using logistic regression (c-statistic: 0.8905 [95% CI:
0.8757-0.9054]).
Comparing risk standardization models
Using the “rocgold” Stata command, the registry data ROC area using the
imputation with a value closest to the median was 0.9069 (95% CI: 0.8949-0.9189)
compared to an administrative ROC area of 0.8905 (95% CI: 0.8755-0.9052). This was
an insignificant difference (p=0.075; Figure 1). Controlling for trend with a BlandAltman plot, we found that the mean difference between the two methods of risk
standardization was 0.002 (95% CI: -0.009-0.014) with a non-significant Pitman's test of
difference in variance (p=0.437), which we conclude represents good agreement; the line
of equality falls within the confidence interval of the mean difference and only 4.97% of
the data points lie outside the recommended range of two standard deviations of the mean
difference. As seen in Figure 2, there is more agreement in the patients with a predicted
poor outcome (Giavarina 2015). Both models had good calibration, as seen in Figures 3
& 4 and by non-significant Hosmer-Lemeshow goodness-of-fit statistics.
Out-of-hospital cardiac arrest
In patients with an out-of-hospital cardiac arrest, 231 of the 1719 candidate
variables identified by the two resuscitation science physician-fellows had a univariate
relationship with survival of p<0.25. Using manual forward selection in order of lowest
p-value to highest, variables were entered into the model, remaining in the model if the
predictive value was improved and removed if the predictive value worsened or remained
11

the same. After analyzing all 231 variables, 98 remained in the model (Appendix Table 3)
with a c-statistic of 0.9346 (95% CI: 0.9178-0.9515) and a Hosmer-Lemeshow goodness
of fit statistic of 0.08. To get a c-statistic>0.80, only 5 variables were needed: codes 96.72
(Continuous invasive mechanical ventilation for 96 consecutive hours or more), 96.04
(Insertion of endotracheal tube), 37.22 (Left heart cardiac catheterization), 414.01
(Coronary atherosclerosis of native coronary artery), and year of arrest. The ROC area for
this reduced model was 0.8011.
The best model for the registry data was the model developed for use in both inand out-of-hospital arrests. This model had an ROC area of 0.9447 (95%CI: 0.93280.9567) when limited to OHCAs. Comparing the registry and administrative models,
there was no significant difference in the ROC areas (p=0.316; Figure 5). Less than 5%
of the data points in the Bland-Altman plot lie outside the recommended range of two
standard deviations of the mean difference (Appendix Figure 1).
In-hospital cardiac arrest
Inpatients with an in-hospital cardiac arrest, 172 of the 1719 candidate variables
identified by the two resuscitation science physician-fellows had a univariate relationship
with survival of p<0.25. Using manual forward selection in order of lowest p-value to
highest, variables were entered into the model, remaining in the model if the predictive
value was improved and removed if the predictive value worsened or remained the same.
After analyzing all 172 variables, 100 remained in the model (Appendix Table 4) with a
c-statistic of 0.8673 (95% CI: 0.8447-0.8898) and a Hosmer-Lemeshow goodness of fit
statistic of 0.065. To attain a c-statistic>0.80, 18 variables were needed: 96.71
(Continuous invasive mechanical ventilation for less than 96 consecutive hours), 96.72
12

(Continuous invasive mechanical ventilation for 96 consecutive hours or more), 599
(Urinary tract infection, site not specified), 43.11 (Percutaneous [endoscopic]
gastrostomy [PEG]), 37.22 (Left heart cardiac catheterization), 37.94 (Implantation or
replacement of automatic cardioverter/defibrillator, total system), V49.86 (presence of a
DNR), 0.17 (infusion of a vasopressor), 429.83 (Takotsubo syndrome), 995.92 (Severe
sepsis), 997.31 (ventilator-associated pneumonia), 8.45 (Intestinal infection due to
clostridium difficile), 37.72 (Initial insertion of transvenous leads [electrodes] into atrium
and ventricle), 50.59 (liver transplant), 570 (acute necrosis of liver), 38.97 (Central
venous catheter placement with guidance), 276.2 (acidosis), and 88.72 (diagnostic
ultrasound of heart). The ROC area for this model is 0.8003.
The best model for the registry data was the model developed for use in both inand out-of-hospital arrests. This model had an ROC area of 0.8629 (95% CI: 0.84120.8846) when restricted to in-hospital arrests. Comparing the registry and administrative
models, there was no significant difference in the ROC areas (p=0.781; Figure 6). Less
than 5% of the data points in the Bland Altman plot lie outside the recommended range of
two standard deviations of the mean difference (Appendix Figure 2).

DISCUSSION
In developing two risk standardization models with extremely small differences
between their c-statistics (0.0164), we have identified that risk adjustment modeling for
cardiac arrest can be performed using administrative data, which are readily available and
less costly (Khuri et al. 1998; Render et al. 2003) and less challenging to compile and to
access than registry data. We therefore have evidence that a tool developed using
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administrative data is feasible and that this model can be optimized for all patients or
stratified by location of arrest. This tool could be applied in research to identify
variability in the management of cardiac arrest and to learn from effective modalities and
protocols to allow hospitals identify opportunities for improvement.
Other studies have used risk standardization in the context of in-hospital cardiac
arrest. One, using nine variables in their model of in-hospital cardiac arrest in the United
States, found a c-statistic of 0.74, and was successful in risk standardizing hospital
survival rates (Chan et al. 2013). Another study of in-hospital cardiac arrest done in the
U.K. found a c-statistic of 0.81 (Harrison et al. 2014). In our work, we had a similar cstatistic in both our registry and administrative models when limited to in-hospital arrests.
In the U.S., there has been found to be a 42% difference in the odds of survival in
in-hospital arrests even after risk adjusting the patient population for comparison
(Merchant et al. 2014). Hospital-level interventions have been shown to be effective
(Adielsson et al. 2011; Fothergill et al. 2013; Fugate et al. 2012; Hollenberg, Svensson,
Rosenqvist 2013; Iwami et al. 2009; Iwami et al. 2012; Japanese Circulation Society
Resuscitation Science Study Group 2013; Kitamura et al. 2010; Kitamura et al. 2012;
Neumar et al. 2008; Peberdy et al. 2010; Ro et al. 2013; Tagami et al. 2012; Weisfeldt et
al. 2010; Wissenberg et al. 2013), and hospitals that perform well with regard to inhospital cardiac arrest have also been found to be better at preventing cardiac arrest
(Chen et al. 2013). Therefore, adequate comparisons, such as those provided using risk
standardization, are vital to improve patient care and outcomes.
A recent study called into question the utility of administrative data for
identifying out-of-hospital cardiac arrest (Coppler et al. 2016). Investigators queried ICD14

9 codes for cardiac arrest as well as VF, paroxysmal ventricular tachycardia, ventricular
flutter, and respiratory arrest and found that only 40% of patients who had these ICD-9
codes had an out-of-hospital cardiac arrest upon chart review. Similarly, we found that
45% of the patients with an ICD-9 code for cardiac arrest were matched with registry
data, although our study only included one ICD-9 code as well as both in- and out-ofhospital cardiac arrests. Although 94% of the cardiac arrests in the registry were able to
be matched to administrative data, there were some significant differences between the
patients who were matched and those who were not. Interestingly, and in concordance
with the above study, all patients who were not matched were able to be successfully
resuscitated, leading to the unmatched patients having significantly better neurologic and
survival outcomes. Despite our ability to risk standardize in a comparable way to registry
data, we do not currently have a way to accurately capture administrative data on the
patient population in question. Further work is needed to develop methods to identify this
population in administrative datasets as well as to elucidate the scope of the problem.
To properly build a nationally representative tool, clustering by site may be
problematic and, although we found similar results using logistic regression compared to
generalized estimating equations and hierarchical mixed effects modeling in our study of
a single health system, those methods may be warranted in multi-site analysis. However,
if the goal is to compare risk-standardized hospital performance, controlling for
clustering by hospital may smooth out important differences at the hospital level; in that
case, logistic regression would be encouraged.
The data from PATH have the limitations of data from any retrospective registry,
including the use of predefined data points and the risk of data entry errors or
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inconsistencies. Additionally, while administrative data potentially are available from all
institutions and can be a reflection of “real world” situations, the information in these
databases are not collected for research purposes, and often key variables are not
recorded by administration, which have non-medical and non-research motivations for
collecting information; these motivations can lead to documentation that might not match
with research documentation. Finally, the data collected by the University of
Pennsylvania Health System may differ from that collected at other institutions, despite
having many common elements, limiting generalizability.

CONCLUSION
This study serves as evidence that risk standardization using administrative data is
comparable to that of registry data in the context of cardiac arrest. The critical gap of
only having information on the performance of a subset of hospitals that participate in a
registry potentially could be addressed by providing support for a new method that may
identify hospital variability. This could lead to the identification of successful strategies
at high-performing hospitals and the targeting of low-performing hospitals for
intervention. Future investigations into expanding this methodology to include more sites
may lead to a new tool for nationwide risk standardization to allow benchmarking and
comparison of hospitals in terms of expected to observed mortality to identify high- and
low-performing hospitals.

16

CHAPTER 2
Degree of temperature elevation is associated with neurologic and survival outcomes
in resuscitated cardiac arrest patients with post-rewarming pyrexia

INTRODUCTION
Significant morbidity and long-term impairments are common in cardiac arrest
survivors (Cronberg et al. 2015; Moulaert et al. 2009; Nichol et al. 2015; Raina et al.
2008; Smith et al. 2015). Approximately half of survivors suffer some degree of
neurologic disability (Moulaert et al. 2009), resulting from ischemic injury occurring
during no- and low-flow states as well as reperfusion injury occurring after restoration of
native circulation. Collectively, this injury pattern is known as post-cardiac arrest
syndrome (PCAS) (Adrie et al. 2002; Neumar et al. 2008). The adverse consequences of
PCAS are frequent but variable, ranging from memory loss and proprioceptive
derangements to persistent vegetative state (Moulaert et al. 2009; Raina et al. 2008), with
impact on long-term function, health, and economic cost. Laboratory and clinical studies
have suggested that elevated temperatures may exacerbate PCAS and subsequent
neurologic injury (Leary et al. 2013; Polderman 2008; Suffoletto et al. 2009; Winters et
al. 2013).
Two randomized trials from 2002 demonstrated that post-arrest therapeutic
hypothermia, also known as targeted temperature management (TTM), improves
neurologic outcomes and survival. In these investigations, patients with out-of-hospital
cardiac arrest (OHCA) with initial shockable rhythms were randomized to prompt
cooling to 32-34°C for 12-24 hours or to passive temperature management (Bernard et al.
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2002; Hypothermia after Cardiac Arrest Study Group 2002). Observational studies have
confirmed these findings for OHCA from shockable rhythms and extended these findings
to other types of cardiac arrest patients (Arrich and European Resuscitation Council
Hypothermia After Cardiac Arrest Registry Study Group 2007; Busch et al. 2006;
Lundbye et al. 2012; Oddo et al. 2006; Perman et al. 2015; Sagalyn et al. 2009; Schefold
et al. 2009; Sunde et al. 2007). However, in part due to concerns that the control groups
in both of the trials trended toward an elevated mean temperature and that a significant
percentage of the control patients had pyrexia, a recent multicenter clinical trial (Nielsen
et al. 2013) randomized both arms to active TTM, 33°C or 36°C. That study found no
significant difference in terms of neurologic outcome or mortality, raising the question of
whether reduced temperature is the protective component of TTM treatment or if
protection is conferred by avoidance of elevated temperatures (Nielsen et al. 2013;
Rittenberger and Callaway 2013).
Development of markedly elevated temperatures (pyrexia), often a response to
cellular injury, activation of inflammatory cascades, or infection (Saper and Breder
1994), is frequent after cardiac arrest (Albrecht, Wass, Lanier 1998; Bouwes et al. 2012;
Cocchi et al. 2014; Merchant et al. 2006; Pichon et al. 2007; Suffoletto et al. 2009;
Takasu et al. 2001; Takino and Okada 1991; Winters et al. 2013; Zeiner et al. 2001). In
diverse groups of patients with encephalopathy, markedly elevated temperatures are often
a marker of poor outcomes and continued physiologic damage (Madden and DeVon
2015; Niven and Laupland 2013; Sadaka 2013; Wrotek et al. 2011); however, whether
this is true in post-arrest patients, particularly those treated with TTM, has yet to be
clearly demonstrated. A connection between pyrexia and worse outcomes in TTM18

treated patients has received support in smaller retrospective studies (Bro-Jeppesen et al.
2013; Gebhardt et al. 2013; Leary et al. 2013; Suffoletto et al. 2009; Winters et al. 2013),
extending findings from earlier research done prior to the adoption of TTM as standard of
care for treatment of anoxic encephalopathy (Albrecht, Wass, Lanier 1998; Langhelle et
al. 2003; Zeiner et al. 2001).
We hypothesized that TTM-treated patients with higher maximum temperatures
following rewarming will have worse outcomes than those with lower maximum
temperatures. We also hypothesized that patients with a longer duration of time at pyrexic
temperatures and with earlier onset of pyrexia will have worse outcomes than those with
a shorter duration.

MATERIALS AND METHODS
To evaluate how body temperature is related to outcomes after reestablishment of
post-TTM normothermia, the Penn Alliance for Therapeutic Hypothermia (PATH)
registry was queried. PATH is an internet-based registry established at the University of
Pennsylvania in 2010 that includes cardiac arrest data from pre-hospital, emergency
department, and in-hospital settings with a focus on post-arrest care. Potentially available
to any US hospital, PATH supports tracking patients who experience cardiac arrest and
receive cardiopulmonary resuscitation. Each record in PATH consists of 30 data
elements required from all participating institutions. One hundred additional data
elements are required for institutions interested in using aggregate PATH data for
research and further optional data elements are also available, including the capability to
collect serial temperature measurements for successfully resuscitated patients. Data are
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entered via a secure website and maintained on a password-protected encrypted server.
Before entering data, data abstractors undergo structured training including mock case
entry and case review. They are provided with a standardized data dictionary and subject
to a formal auditing process (Leary et al. 2013). PATH currently supports 34 member
hospitals and includes data from >5000 cardiac arrests. This project was approved by the
University of Pennsylvania Institutional Review Board.
Serial temperatures in the 72 hours following reestablishment of post-TTM
normothermia (defined as reaching ≥36.5°C (Bro-Jeppesen et al. 2013) after a period of
TTM treatment at temperature of ≤34.0°C) were evaluated. Only patients who received
TTM were included. Exclusion criteria were: age <18 years; traumatic etiology of arrest;
death in the first 24 hours post-arrest; and no recorded temperatures during the applicable
time period. Patients also were excluded if target temperature (≤34°C) was never
achieved or if they did not survive until completion of the rewarming phase of TTM.
Both OHCA and in-hospital cardiac arrests (IHCA) were included. Pyrexia was defined
as 38.0°C, which has been used in other post-cardiac arrest studies on the effects of
temperature (Benz-Woerner et al. 2012; Bouwes et al. 2012; Bro-Jeppesen et al. 2013;
Gebhardt et al. 2013; Leary et al. 2013; Suffoletto et al. 2009; Winters et al. 2013). The
primary outcome was neurologic status (measured by a Cerebral Performance Category
(CPC) score dichotomized into “favorable” [CPC 1-2] and “unfavorable” [CPC 3-5]) and
the secondary outcome was survival, both measured at hospital discharge. CPC has been
used frequently as an outcome measure in prior clinical studies of cardiac arrest (Bernard
et al. 2002; Hypothermia after Cardiac Arrest Study Group 2002; Nielsen et al. 2013).
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There were three predefined exposures: maximum temperature, duration of pyrexia, and
timing of onset of first pyrexic temperature (described below); maximum temperature
was the primary analysis for which the study was powered.
Maximum temperature
Maximum temperature was defined as the highest recorded temperature in the 72
hours after completion of TTM and rewarming. Multiple classification approaches were
used to account for different possibilities of how maximum temperature related to
outcomes: as a continuous variable, as an ordinal variable (by single temperature degree),
and as a dichotomous variable (≥38.0°C, yes/no) in separate models. Of note, 118 (25%)
of the patients evaluated for maximum temperature were included in previous work
analyzing temperature elevation (Leary et al. 2013), although the patients in that study
were followed for 48 hours instead of 72 hours and normothermia was defined as 37.0oC
instead of 36.5°C. In that project, duration of pyrexia and timing of onset were not
analyzed, so the patients were shared only when the effects of maximum temperature
were analyzed.
Duration of pyrexia
The duration of time a patient experienced a certain temperature (or above) was
calculated by assigning half of the time at a pyrexic temperature and half of the time at a
non-pyrexic temperature when the patient transitioned between a pyrexic to a nonpyrexic point (and vice versa). This calculation ended 72 hours post-rewarming and was
repeated for every tenth of a degree, beginning with 38.0°C and ending with 42.2°C (the
highest recorded temperature), to calculate the duration of time at or above each tenth of
a degree. This was to assess whether duration of time at different temperatures (e.g.
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38.0°C, 38.1°C, 38.2°C,...42.2°C) had different relationships to outcomes. Due to
diversity in maximum temperature cutoffs across studies (Leary et al. 2013; Winters et al.
2013), we analyzed each tenth of a degree to allow for a data-driven temperature
threshold, as opposed to one that was predefined. Each measure of time was treated first
as a continuous variable (hours at temperature of interest) and then as an ordinal variable
(divided by tertile) for each temperature cut point.
Timing of onset of pyrexia
Timing of onset of pyrexia was defined as the time between the patient’s return to
normothermia and the first recorded pyrexic temperature (≥38°C). Timing of onset of
pyrexia was assessed in 4 ways: early (first 36 hours post-normothermia) vs. late (second
36 hours post-normothermia) onset, continuously (time from normothermia to first
temperature ≥38°C in hours), in deciles, and in groups determined by Jenks natural break
optimization, a statistical technique that uses the distribution of data to determine
naturally occurring groupings (Cox 2007; Jenks 1967). We also explored whether timing
of onset of a temperature higher than 38.0°C was associated with outcomes; this
temperature was chosen by comparing the univariate areas under the curve (AUCs) in
relation to outcomes and selecting the temperature with the best discrimination.
Patient types
To combine all three elements of temperature examined in pyrexic patients, 12
different patient categories were created based on naturally occurring groupings, as
determined by Jenks natural break optimization (Cox 2007; Jenks 1967). There were two
groups of maximum temperature (low versus high), two groups of duration of pyrexia
(short versus long) and three groups of timing of onset of pyrexia (early versus middle
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versus late; Appendix Table 5). Patient types then were analyzed with regard to
outcomes. Due to some patient types having a low number of patients, 16 patient types
were created involving just two dimensions of temperature and the analyses were
repeated.
Other data analysis
For each dimension of temperature analysis, pre-, intra-, and post-arrest variables
recorded in PATH (Appendix Table 6) were examined to explore potential confounders.
Descriptive statistics used proportions, means and standard deviations, medians and
interquartile ranges, and histograms to determine the proportion or prevalence and
distribution of each variable. Each potential confounder was modeled separately with the
outcome prior to use in a multivariate model. Any multivariate analyses used p<0.25 for
covariate entry into the model (Maldonado and Greenland 1993; Mickey and Greenland
1989). A parsimonious model was then created using backward stepwise procedures and
likelihood ratio tests (Lemeshow and Hosmer 1982). Less than 15% of data on covariates
was missing; missing data on covariates was addressed using multiple imputation
conducted using 20 iterations (StataCorp 2013) and then combined using the “mi
estimate” Stata command (Cañette and Marchenko 2013). Regression results were
reported using odds ratios (ORs) and corresponding 95% confidence intervals (CIs). All
data were analyzed using Stata v13.1 (Statacorp, College Station, TX). Additional
analyses stratified by location of arrest (OHCA/IHCA) were performed, since IHCA
patients are more likely to have multi-organ dysfunction and thus have elevated
temperatures from other causes (Winters et al. 2013) and restricted to only patients with a
maximum temperature ≥38.0°C. Finally, each component, maximum temperature,
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duration of pyrexia, and timing of onset of pyrexic temperature, was tested to assess
whether there was a univariate “threshold” value using receiver operating characteristic
(ROC) curves and concordance statistics for discrimination. Post-estimation HosmerLemeshow goodness of fit tables were used to assess validity of each chosen cut-off.

RESULTS
Out of 465 TTM-treated patients from 13 hospitals in the PATH registry treated
between 2005-2015 who met inclusion criteria, 179 (38.5%) had at least one pyrexic
temperature (≥38°C). Pyrexic patients had a mean age of 56.0±16.0 years, 59.8% were
male, 39.5% had an initial shockable rhythm, 69.4% had a witnessed arrest, 65.9% had a
suspected cardiac etiology of arrest, and 83.2% were OHCA (Table 2). In terms of
demographics, they only differed significantly from non-pyrexic patients in terms of age
(pyrexic: 56.0±16.0 versus non-pyrexic: 60.4±16.4; p=0.001). However, the relationship
between temperature and outcomes was not modified by age.
Maximum temperature
Our primary analysis, examining the effect of maximum temperature on
neurologic outcome, controlling for age, duration of arrest, whether the arrest was
witnessed, location of arrest, and initial rhythm, found that higher maximum temperature
was associated with worse neurologic outcome (aOR: 0.30 [95% CI: 0.10-0.84],
p=0.022) and lower survival (aOR: 0.25 [95% CI: 0.10-0.59], p=0.002; Table 3A) in
patients who experienced post-rewarming pyrexia (Figure 7).
When analyzing the role of pyrexia (maximum temperature: ≥38.0°C) versus nonpyrexia (maximum temperature: <38.0°C), there was no significant relationship with
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neurologic outcome (Table 3B), although there was a protective effect for pyrexia with
regard to survival. Further analysis revealed that this was largely driven by IHCA
patients, and that, when analyzing only patients with a maximum temperature of ≥37°C,
the difference became non-significant.
Duration of pyrexia
There was no significant relationship between duration of pyrexia and outcomes
unless duration was calculated as time a patient experienced temperature 38.8°C. This is
the lowest temperature at which significant associations were found with regard to either
the primary or secondary outcome. When measuring duration of temperature 38.8°C,
there was a significant association between longer duration and worse neurologic
outcome and lower survival (Table 3C). This relationship was similar when duration was
measured against survival as time with temperature 38.9°C for neurologic outcome and
for all subsequent tenths of a degree until 39.5°C.
Timing of onset of pyrexia
There was no significant relationship between the timing of onset of a temperature
≥38.0°C and outcomes (aOR for neurologic outcome: 1.01 [95% CI: 0.99-1.04], p=0.233;
aOR for survival: 1.02 [95% CI: 1.00-1.04], p=0.129). When pyrexia onset was measured
as first time 38.7°C (the value with the best AUC in univariate analysis with regard to
neurologic outcome [0.603 for neurologic outcome and 0.609 for survival]), there were
no significant differences (aOR for neurologic outcome: 1.03 [95% CI: 0.99-1.08],
p=0.168; aOR for survival: 1.01 [95% CI: 0.98-1.04], p=0.535).
Patient types
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Combining these elements into “patient types,” the patients with high
temperatures always had lower (worse) point estimates than their low temperature
counterparts, regardless of other factors. This difference was statistically significant for
both neurologic outcome and survival when comparing the high temperature/early
pyrexia group to the low temperature/early pyrexia group (CPC 1-2: OR: 0.33 [95% CI:
0.14-0.77], p=0.011; survival: OR: 0.25 [95%CI: 0.08-0.79], p=0.018). Compared to the
low temperature/short duration group, the high temperature/long duration group was
statistically worse in terms of neurologic status (OR: 0.36 [95% CI: 0.16-0.83], p=0.017).
Comparing the low temperature/long duration group to the high temperature/long
duration group and to the high temperature/short duration group, the higher temperature
groups had worse survival (high temperature/long duration OR: 0.35 [95% CI: 0.160.79], p=0.011; high temperature/short duration OR: 0.24 [95% CI: 0.07-0.90], p=0.034).
There were no significant differences in either outcome for the patient types that included
only duration and timing of onset. There were similar findings with regard to survival and
neurologic outcome when the analysis was restricted to OHCA patients.
Using all three temperature elements to determine “patient type”, there were
significantly worse neurologic outcomes in the high temperature /long duration/early
pyrexia group compared to the low temperature/long duration/early pyrexia group (OR:
0.25 [95% CI: 0.08-0.77], p=0.016). There also were significantly worse survival
outcomes in both the high temperature/long duration/early pyrexia group (OR: 0.31 [95%
CI: 0.11-0.89], p=0.029) and the high temperature/short duration/early pyrexia group
(OR: 0.12 [95% CI: 0.02-0.69], p=0.017) when compared to the low temperature/long
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duration/early pyrexia group. There were similar findings with regard to survival and
neurologic outcome when the analysis was restricted to OHCA patients.
Other data analysis
Each component, maximum temperature, duration of pyrexia, and timing of onset
of pyrexia, was tested to examine if there was a univariate “threshold” value using
receiver operating characteristic (ROC) curves and concordance statistics for
discrimination. There was no cut-off value that was predictive of outcomes by itself (data
not shown).

DISCUSSION
In this study of serial temperatures examining TTM-treated post-arrest patients
with pyrexia, there was a linear relationship between increasing maximum temperature
and worsening neurologic and survival outcomes. There was no significant difference
between the two other aspects of pyrexia, duration and timing, except, in the case of
duration, where the risk of pyrexia increased with hours at a very elevated temperature
(≥38.8°C). The importance of elevated temperatures in terms of post-arrest outcomes was
reinforced when, using all three temperature elements to determine “patient type”, higher
(more favorable) point estimates for all low temperature types compared to their high
temperature counterparts were found, as well as statistically worse outcomes when
comparing high temperature groups to their low temperature counterparts holding the
other temperature elements constant. This suggests a critical link between high
temperature and neurologic injury in patients experiencing post-rewarming pyrexia; thus,
avoidance of high temperatures might improve outcomes.
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Prior clinical studies have demonstrated the complexity of assessing the
relationship between post-arrest temperature and outcomes. A recent investigation found
that post-rewarming pyrexia was associated with favorable survival and neurologic
outcomes. However, the mean maximum temperature in this work was 37.5°C (range:
36.8-38.1°C), which supports the finding of this study that mild pyrexia may not provoke
injury; in fact, markedly elevated temperatures may pose the problem with regard to
outcomes (Lee et al. 2015). Other studies, defining pyrexia as ≥38.0°C, also found no
relationship between being above this temperature and outcomes (Bouwes et al. 2012;
Cocchi et al. 2014). A study analyzing both patients who received TTM and those who
did not found that pyrexia (defined as ≥38.0°C) had no association with neurologic
outcomes and was not associated with survival within the whole cohort or the patients
who received TTM, but was associated with lower survival in patients who did not
receive TTM, which could be explained by the difference in maximum temperature in the
TTM group (37.61.0°C) compared to the non-TTM group (38.21.0°C) (Gebhardt et al.
2013). Suffoletto et al found that patients experiencing post-arrest pyrexia (≥38.0°C) had
worse survival and neurologic outcomes; however, the vast majority of the patients in this
study did not receive TTM and mean maximum temperature in the pyrexic group was not
reported (Suffoletto et al. 2009).
Examining elevated pyrexia after TTM, defined as ≥38.5°C in the first 24 hours
after TTM cessation, Winters et al found an association between a temperature ≥38.5°C
and worse outcomes with regard both to survival and neurologic status, consistent with
the results of this study (Winters et al. 2013). Similarly, our previous work (as mentioned
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in the Methods section) found no association between patients experiencing pyrexia when
defined as ≥38.0°C and outcomes, but did find that patients with “marked pyrexia”
(>38.7°C) compared to those who experienced no/mild pyrexia (38.7°C)) had
significantly worse neurologic outcomes at hospital discharge (Leary et al. 2013).
Two recent randomized trials, one in adults (“TTM trial”) (Nielsen et al. 2013)
and one in children (Therapeutic Hypothermia After Pediatric Cardiac Arrest trial, or
THAPCA) (Moler et al. 2015), randomized patients to receive active TTM at different
goal temperatures, 33°C versus 36°C in the TTM trial and 33°C versus 36.8°C in the
pediatric THAPCA trial. The null results from these studies raise questions regarding
mechanisms by which TTM confers benefit: whether physiologic changes resulting from
mild hypothermia or prophylaxis against pyrexia is the vital component (Rittenberger and
Callaway 2013; Rittenberger and Callaway 2014). Although both studies failed to find a
significant difference between the two temperature goals, the second study has been
criticized as potentially underpowered – that the trend toward more positive outcomes in
the group at goal temperature 33.0°C (p=0.14) is not statistically significant simply
because there were not enough patients in the study (Geva, Tasker, Randolph 2015;
Riess, Aufderheide, Yannopoulos 2015). One possible explanation for the statistical
differences in the two studies is in the different temperatures for the “normothermia” arm
(36.0°C compared to 36.8°C). In the TTM trial, a goal body temperature of 36°C resulted
in an upper limit of the 95% confidence interval of recorded temperatures being between
37.0-37.5°C; these patients were well protected from pyrexia (van der Jagt and Haitsma
2015). The THAPCA trial, with its goal temperature 0.8°C higher than the 36°C arm in
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the TTM trial may not provide the same protection against temperatures ≥38.0°C with
similar confidence bounds, although this is not necessarily the case. If higher
temperatures are indeed indicative of worsened outcomes, then permitting higher
temperatures may be associated with worse outcomes, which may explain the trend
toward better results in THAPCA patients treated at 33°C (Moler et al. 2015).
This argument is supported by studies of the physiologic effects of elevated
temperature on the brain. Laboratory investigations have suggested that a broad array of
post-arrest pathophysiological processes is worsened by hyperthermia (Polderman 2008;
Winters et al. 2013). Avoidance of pyrexia has been recommended in international
resuscitation guidelines (Deakin et al. 2010; Peberdy et al. 2010), as pyrexia induces
inflammatory cascades and increases neuronal excitotoxicity with neurotransmitter
release, free radical production, increased intracellular glutamate concentration (Badjatia
2009; Zhao et al. 1997), neuroinflammation, influx of excess calcium into injured brain
cells leading to hyper-metabolism, trapping of heat in injured areas (Polderman 2009),
and a generalized increase in metabolic rate (Lanier 1995; Polderman 2008; Polderman
2009; Polderman 2015). As demonstrated in animal studies, high brain temperature,
independent of initial severity of injury, can cause additional neurological damage
(Polderman 2009; Wang et al. 2009). There is also a relationship between temperature
changes and ischemia; post-ischemic injury is aggravated under hyperthermia (Busto et
al. 1987; Dietrich et al. 1990; Kobayashi et al. 2008). This provides a scientific rationale
for these findings on the deleterious effects of more markedly elevated temperatures.
A number of limitations are inherent in this work. This study represented an
analysis of a retrospective registry. As such, this study was limited to using predefined
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data points and has the risk of data entry errors or inconsistencies. Additionally, there
may be information bias if the highest temperature was not recorded in the patient chart,
which could result in misclassification. As a retrospective study, whether increased body
temperature causes brain injury directly or merely acts as a surrogate marker for more
severely damaged patients (Bro-Jeppesen et al. 2013; Winters et al. 2013) cannot be
tested, although these findings are consistent with a large body of mechanistic work.
Despite these limitations, use of a registry allows for a heterogeneous patient population,
leading to greater external validity and generalizability.

CONCLUSIONS
In patients experiencing post-rewarming pyrexia, higher temperatures are
associated with worse outcomes. Longer duration of time at pyrexic temperatures is only
associated with worse outcomes at high temperatures (≥38.8°C), suggesting that
avoidance of markedly elevated temperatures might improve outcomes.
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CHAPTER 3
Degree, duration, and timing of temperature elevation are associated with
neurologic and survival outcomes in resuscitated cardiac arrest patients with postarrest pyrexia

INTRODUCTION
Approximately half of sudden cardiac arrest survivors suffer some degree of
neurologic disability (Moulaert et al. 2009) from massive ischemic injury and subsequent
reperfusion processes, known collectively as the post-cardiac arrest syndrome (PCAS)
(Adrie et al. 2002; Neumar et al. 2008). Two randomized trials published in 2002
demonstrated that post-arrest therapeutic hypothermia, also known as targeted
temperature management (TTM), greatly improves neurologic outcomes and survival
when applied early after successful resuscitation from out of hospital cardiac arrest
(OHCA) associated with an initial shockable rhythm (VF/VT)) (Bernard et al. 2002;
Hypothermia after Cardiac Arrest Study Group 2002). A large number of observational
studies have confirmed and extended these findings, including evidence that TTM can be
applied to arrests caused by other rhythms and to IHCA (Arrich and European
Resuscitation Council Hypothermia After Cardiac Arrest Registry Study Group 2007;
Busch et al. 2006; Lundbye et al. 2012; Oddo et al. 2006; Perman et al. 2015; Sagalyn et
al. 2009; Schefold et al. 2009; Sunde et al. 2007). However, a recent study from Europe
(Nielsen et al. 2013) has challenged the current paradigm of post-arrest TTM. This
investigation differed from the trials in 2002 in that both arms of the trial received active
TTM, each with a different goal temperature: a “hypothermic” group with a goal of 33°C
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and a “normothermic” group with an actively managed goal of 36°C. The study found no
significant difference in terms of neurologic outcome or mortality, which has raised the
question of whether mild hypothermia is the important component of TTM treatment or if
the avoidance of elevated temperatures is (Nielsen et al. 2013; Rittenberger and Callaway
2013).
Because patients treated with TTM have their temperatures controlled, potentially
masking variation and preventing extreme temperatures, we sought to explore the
relationship between three different elements of post-arrest temperature and outcomes in
patients not treated with TTM. Although studies examining the role of temperature in
post-arrest patients prior to the widespread use of TTM exist, post-arrest care has
changed dramatically since those works were conducted (Callaway et al. 2015; Hinchey
et al. 2010; Kellum, Kennedy, Ewy 2006; Kellum et al. 2008; Lund-Kordahl et al. 2010;
Neumar et al. 2008; Spaite et al. 2014). Additionally, the population of patients not
treated with TTM has changed. The most recent studies evaluating post-arrest
temperature include patients treated with TTM (Gebhardt et al. 2013; Suffoletto et al.
2009), causing difficulty in effectively ascertaining the effects of temperature in patients
not treated with TTM, a group that could serve to inform comparisons regarding the
protective mechanisms of TTM (Rittenberger and Callaway 2013). Investigation of
patients not treated with TTM provides an opportunity to expand the scientific
understanding of neurologic mechanisms underlying PCAS and post-arrest temperature.

METHODS
To evaluate how body temperature during the 72 hours following successful
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resuscitation from cardiac arrest is related to outcomes, the Penn Alliance for Therapeutic
Hypothermia (PATH) registry was queried. PATH is an internet-based registry
established by University of Pennsylvania investigators in 2010 that includes cardiac
arrest data from pre-hospital, emergency department, and in-hospital settings with a focus
on post-arrest care. With participation open to any US hospital, PATH supports the
tracking of all patients who experience cardiac arrest and receive cardiopulmonary
resuscitation, and currently includes cases from 34 hospitals. Each patient record in
PATH consists of 30 data elements required from all participating institutions. One
hundred additional data elements are required for research participation and further
optional data elements are also available to address specific research questions. Data are
entered via a secure website, maintained on a password-protected encrypted server at the
University of Pennsylvania, and collected retrospectively at each participating institution
by trained PATH clinical data collection volunteers. Before entering data, data
abstractors undergo structured training including mock case entry and case review. They
are provided with a standardized data dictionary and subject to a formal auditing process
(Leary et al. 2013). PATH currently supports 34 member hospitals and includes data
from over 5000 cardiac arrests. PATH includes the capability of collecting serial
temperature measurements for successfully resuscitated patients.
Serial temperatures in the 72 hours after successful resuscitation from cardiac
arrest were evaluated in the current study. Only patients who did not receive TTM were
included. Exclusion criteria were age <18 years; traumatic etiology of arrest; death in the
first 24 hours post-arrest; and no recorded temperatures during the applicable time period.
Both OHCA and IHCA were included. Pyrexia was defined as 38.0°C, consistent with
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definitions used in other post-cardiac arrest studies on the effects of temperature (BenzWoerner et al. 2012; Bouwes et al. 2012; Bro-Jeppesen et al. 2013; Gebhardt et al. 2013;
Leary et al. 2013; Suffoletto et al. 2009; Winters et al. 2013); additionally, this
temperature is also used as part of systemic inflammatory response syndrome (SIRS)
criteria in sepsis, a condition that has been found to have much in common with PCAS
(Adrie et al. 2002; Neumar et al. 2008). Our primary outcome was neurologic status
(measured by a Cerebral Performance Category (CPC) score dichotomized into
“favorable” [CPC 1-2] and “unfavorable” [CPC 3-5]) and our secondary outcome was
survival, both measured at hospital discharge. The CPC score measured at discharge has
been found to be reliable in terms of predicting long-term prognosis, especially survival
(Hsu et al. 2014; Pachys et al. 2014; Phelps et al. 2013). There were three predefined
exposures: maximum temperature, duration of pyrexia, and timing of onset of first
pyrexic temperature (described below); maximum temperature was the primary analysis
for which the study was powered.
Maximum temperature
Maximum temperature was defined as the highest recorded temperature in the 72
hours immediately post-arrest. Multiple classification approaches were used to account
for different possibilities of how maximum temperature related to outcomes: as a
continuous variable, as an ordinal variable (by one temperature degree), and as a
dichotomous variable (≥38.0°C, yes/no) in separate models.
Duration of pyrexia
The duration of time a patient experienced a pyrexic temperature was calculated
in three ways: a low estimate (included time between consecutive pyrexic temperatures
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with an assumed 1 hour buffer for a pyrexic temperature followed by a non-pyrexic
temperature (or vice versa)) (Gebhardt et al. 2013), a high estimate (included time
between consecutive pyrexic temperatures with all time from the pyrexic temperature to
the next non-pyrexic temperature recorded) (Gebhardt et al. 2013), and an estimate that
assumed that the transition between a pyrexic to a non-pyrexic point indicated half of the
time at a pyrexic temperature and half of the time at a non-pyrexic temperature. All
estimates ended at 72 hours post-arrest. These calculations were repeated for every tenth
of a degree, beginning with 38.0°C and ending with 42.6°C (the highest recorded
temperature for any patients during the time period of interest), to measure the duration
of time at or above each tenth of a degree and assess whether duration of time at
increasing temperatures (e.g., 38.0°C, 38.1°C, 38.2°C, ….42.6°C) had different
relationships to outcomes. Due to diversity in maximum temperature cut points across
studies (Takino and Okada 1991; Zeiner et al. 2001), we analyzed each tenth of a degree
to allow for a data-driven temperature threshold, as opposed to one predefined. Each
measure of time then was treated first as a continuous variable (hours at temperature of
interest), as an ordinal variable (divided by tertile), and as a dichotomous variable
(above/below the median duration) for each temperature cut point.
Timing of pyrexia onset
Timing of onset of pyrexia was defined as the time between return of spontaneous
circulation and the first recorded pyrexic temperature (≥38.0°C). Timing of onset of
pyrexia was assessed in 5 ways: early (first 36 hours post-arrest) vs. late (second 36 hours
post-arrest) onset, early (before the median) vs. late (after the median) onset, as a
continuous variable (time from arrest to first temperature ≥38.0°C in hours), in deciles,
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and in groups established using Jenks natural break optimization, a statistical technique
that uses the distribution of data to determine naturally occurring groupings (Cox 2007;
Jenks 1967).
Patient types
To combine all three elements of temperature examined in patients with a
maximum temperature ≥38.0°C, 12 different patient types were created based on
naturally occurring groupings, as determined by Jenks natural break optimization (Cox
2007; Jenks 1967). There were two groups of maximum temperature (low versus high),
two groups of duration of pyrexia (short versus long) and three groups of timing of onset
of pyrexia (early versus middle versus late). These patient types then were analyzed with
regard to neurologic and survival outcomes. Due to some patient types having a low
number of patients, 16 additional patient types were created involving just two
dimensions of temperature and the analyses were repeated.
Other data analysis
For maximum temperature, duration of pyrexia, and timing of onset of pyrexia,
pre-, intra-, and post-arrest variables recorded in PATH were examined to explore
potential confounders. Descriptive statistics used proportions, means and standard
deviations, medians and interquartile ranges, and histograms to determine the proportion
or prevalence and distribution of each variable. Each potential confounder was modeled
separately with the outcome prior to use in a multivariate model. Any multivariate
analyses used p<0.25 for covariate entry into the model (Maldonado and Greenland 1993;
Mickey and Greenland 1989). Parsimonious models were created using backward
stepwise procedures and likelihood ratio tests (Lemeshow and Hosmer 1982). Missing
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data on covariates of more than 5% but no more than 15% were addressed using multiple
imputation conducted using 20 iterations (StataCorp 2013) and combined using the “mi
estimate” Stata command (Cañette and Marchenko 2013). Regression results were
reported using odds ratios (ORs) and corresponding 95% confidence intervals (CIs). All
data were analyzed using Stata v13.1 (Statacorp, College Station, TX). Additional
analyses stratified patients by location of arrest (OHCA/IHCA) and by whether the
patient regained arousal shortly post-arrest or remained comatose. Finally, each
component, maximum temperature, duration of pyrexia, and timing of onset of pyrexic
temperature, was tested to assess whether there was a univariate “threshold” value using
receiver operating characteristic (ROC) curves and concordance statistics for
discrimination. Post-estimation Hosmer-Lemeshow goodness of fit tables were used to
assess the validity of each chosen cut-off.

RESULTS
Out of 578 patients from 8 hospitals in the PATH registry treated from 2001-2015
who met inclusion criteria, 228 (39.5%) had at least one pyrexic temperature (≥38.0°C).
Approximately 90% of patients with a pyrexic temperature had data regarding timing of
pyrexia onset (206/228) and duration of pyrexia (205/228). Patients had a median age of
65 (IQR: 55, 74) years, a median 7 (IQR: 3, 15) minute duration of arrest, 31.7% had an
initial shockable rhythm, 30.8% were OHCA, and 57.3% regained arousal (defined as not
eligible for TTM due to purposeful following of commands) shortly post-arrest. With
regard to outcomes, 62.3% of patients survived to hospital discharge; 84.7% had a CPC
score of 1 or 2 at discharge. Pyrexic patients only differed significantly from non-pyrexic
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patients in terms of median age (pyrexic: 64 (IQR: 52, 72) versus non-pyrexic: 66 (IQR:
56, 75); p=0.01), median duration of arrest (pyrexic: 8 (IQR: 4, 17) versus non-pyrexic: 6
(IQR: 2, 14); p=0.01), and whether the patient regained arousal shortly post-arrest
(pyrexic: 49% versus non-pyrexic: 63%, p=0.001; Table 4).
Maximum temperature
When examining the effects of maximum temperature on outcome in multivariate
analysis, controlling for duration of arrest, whether the arrest was witnessed, location of
arrest, initial rhythm, if intra-arrest epinephrine was given, etiology of arrest, whether the
patient regained arousal shortly post-arrest, time between arrest and maximum
temperature, year of arrest, and treating hospital, increased maximum temperature was
significantly associated with worse outcomes in all pyrexic patients, in patients with an
OHCA, and in patients who remained comatose after successful resuscitation (Table 5A).
When analyzing the effect of a maximum temperature of <38.0°C versus
≥38.0°C, there was a trend toward an opposite result; a temperature ≥38.0°C appeared to
be protective with regard to neurologic outcome in all patients and in patients
experiencing an IHCA and with regard to both neurologic outcome and survival in
comatose patients (Table 5B), compared to a temperature <38.0°C. These results were the
same when analyzed by ordinal temperature degree. There was no temperature threshold
that was independently predictive of outcome.
Duration of pyrexia
There was no significant relationship between duration of pyrexia and outcomes
in all patients unless duration was calculated as time ≥38.7°C, the first temperature that
had a significant association with outcomes. When measuring duration of temperature
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≥38.7°C, there was a significant association between longer duration and worse
neurologic outcome and lower survival. When restricted to only OHCAs, longer duration
was significantly associated with worse neurologic outcome and lower survival starting at
a temperature of 38.3°C. Once duration of pyrexia was measured at 39.0°C, all patients,
patients with an OHCA, patients with an IHCA, and patients who regained arousal
shortly post-arrest had a significant association between longer duration and worse
outcomes. Only patients who remained comatose did not have a significant association
(Table 6). There was consistency between all three measures of duration of pyrexia; the
reported results are from the estimate that assumed that the transition between a pyrexic
to a non-pyrexic point indicated half of the time at a pyrexic temperature and half of the
time at a non-pyrexic temperature, which represents the most moderate calculation.
There were suitable pyrexia duration threshold values to serve as an independent
predictor of outcome for all patients, patients with an OHCA, patients with an IHCA, and
patients who regained consciousness shortly post-arrest. These thresholds ranged from
2.5-6 hours at a certain pyrexic temperature, and varied due to strata of arrest and
temperature measured (Table 7).
Timing of pyrexia onset
The relationship of the timing of onset of pyrexia to outcome varied by which
subgroup of patients was analyzed: in comatose patients, both middle (10.2-24.5 hours
post-arrest) and late (25.5-70.4 hours post-arrest) onset were associated with worse
outcomes than early (0.2-10.0 hours post-arrest) onset. In all patients and those with
OHCAs, the relationship was quadratic, with early and late onset being associated with
better outcomes than middle onset in all patients and associated with better neurologic
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outcome in OHCAs (Table 8; characteristics of patients based on their onset of pyrexia
timing in Appendix Table 7). When limited to timing of onset of a temperature ≥38.8°C,
there was some evidence that this pattern of timing held, but power constraints due to the
reduced number of patients in each stratum precluded associative conclusions. There was
no threshold value at which timing of pyrexia onset independently predicted outcomes.
Patient types
Combining these elements into “patient types” (Appendix Table 8), both timing of
onset of pyrexia and maximum temperature were found to be associated with outcomes.
Higher maximum temperature and timing of pyrexia onset between 10.2-24.5 hours postarrest were associated with worse outcomes. Patients with a low maximum temperature
(38.0-39.0°C) and a timing of onset of pyrexia between 10.2-24.5 hours had significantly
worse outcomes than a patient with a low maximum temperature and an early onset of
pyrexia (0.0-10.5 h) (OR for CPC 1-2: 0.26 [95% CI: 0.10-0.67], p=0.01; OR for
survival: 0.35 [95% CI: 0.13-0.93], p=0.04), as did a patient with a high maximum
temperature (39.1°-42.6°C) and an early onset of pyrexia (OR for CPC 1-2: 0.26 [95%
CI: 0.09-0.76], p=0.02; OR for survival: 0.17 [95% CI: 0.06-0.51], p<0.01; Figure 8).
The importance of timing of pyrexia onset and maximum temperature was
especially pronounced in patients who remained comatose, with worse neurologic
outcomes in patients with a low maximum temperature (38.0-39.0°C)/short duration of
pyrexia (0.0-10.5h)/middle timing of pyrexia onset (10.2-24.5h), patients with low
temperature/short duration/late timing of pyrexia onset (25.5-70.4h), patients with high
maximum temperature (39.1-42.6°C)/long duration of pyrexia (10.5-54.1h)/early timing
of pyrexia onset (0.2-10.0h), patients with high temperature/long duration/middle timing,
41

and patients with high temperature/long duration/late timing compared to patients with
low temperature/short duration/early timing. In terms of survival, patients with low
temperature/short duration/middle timing, high temperature/long duration/early timing,
and high temperature/long duration/late timing had worse survival compared to patients
with low temperature/short duration/early pyrexia (Table 9).
Other data analysis
There was no univariate “threshold” value using receiver operating characteristic
(ROC) curves that would allow for independent prediction of outcome for either
maximum temperature or timing of onset of pyrexia.

DISCUSSION
In this study of 578 post-arrest patients not treated with TTM, multiple aspects of
post-arrest temperature were found to be important: maximum temperature, the
combination of maximum temperature and duration of time at an elevated temperature,
and timing of onset of pyrexia. We found a linear relationship between increasing
maximum temperature and worsening neurologic and survival outcomes in pyrexic
patients, although a seemingly protective effect of mild pyrexia when compared to
37.0°C, which suggests that pyrexia is harmful at temperatures >38.0°C, the traditional
definition of an elevated temperature (Benz-Woerner et al. 2012; Bouwes et al. 2012;
Gebhardt et al. 2013; Leary et al. 2013; Neumar et al. 2008; Suffoletto et al. 2009;
Winters et al. 2013). This was supported by the finding that there were discrete durations
of time at or above certain pyrexic temperatures that were predictive of outcome, and that
higher temperatures had lower duration thresholds (for example, in OHCAs, a cutoff of
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≤5 hours at 38.8°C and a cutoff of ≤2.5 hours at 39.5°C both had excellent predictive
value; in other words, patients could experience temperatures at 38.8°C for twice as long
than they could at 39.5°C before the effects of pyrexia became detrimental). Finally, we
found that timing of onset of pyrexia was associated with outcomes, in a manner than
might partially mirror the phases of PCAS syndrome: early (0.2-10.0 hours), middle
(10.2-24.5 hours), and late (25.5-70.4 hours). In the patients who remained comatose
post-arrest (those most likely to have PCAS) (Neumar et al. 2008), both the patients with
middle and late timing of pyrexia onset, which have similar timing to the “intermediate”
PCAS phase (Neumar et al. 2008), are associated with worse outcomes. This could reflect
the impact of the systemic ischemia/reperfusion response.
Similarly, relatively small clinical studies conducted prior to the widespread use
of TTM support an association between pyrexia and poor outcomes in post-arrest patients
(Bro-Jeppesen et al. 2013; Langhelle et al. 2003; Takasu et al. 2001; Takino and Okada
1991; Zeiner et al. 2001). However, Takino et al found that hyperthermia (defined as
>38.0°C) was associated with poor neurologic outcomes and temperatures above 39.0°C
were associated with brain death (Takino and Okada 1991). In another clinical study,
Zeiner et al found that for each degree over 37°C, the risk of an unfavorable neurologic
recovery increased, with an odds ratio of 2.26 (Zeiner et al. 2001), which contradicts our
finding that mild pyrexia is not harmful, but supports our assertion that temperature
elevation beyond that is associated with worse outcomes. One explanation for our
contradictory results is that mild pyrexia could be protecting against the infection
commonly seen in post-arrest patients (Hypothermia after Cardiac Arrest Study Group
2002; Sunde et al. 2007) by temporarily enhancing the immune system (Kluger et al.
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1996; Mace et al. 2011; Repasky, Evans, Dewhirst 2013). Another possibility is that the
patient populations studied are different.
Another study analyzed the effects of post-arrest duration of pyrexia, examining
336 patients in the first 48 hours post-arrest, 65% of whom received TTM. We replicated
their methodology in measuring duration of pyrexia for two of our three estimates of
pyrexia duration, the low and high estimate. While both low and high duration estimates
were associated with neurologic outcome in the patients treated with TTM in their study,
there was no relationship between duration of pyrexia (defined as ≥38.0°C) and
neurologic outcome in the patients not treated with TTM, which supports our finding
when duration was analyzed at a temperature ≥38.0°C (Gebhardt et al. 2013). Another
study of patients suffering from traumatic brain injury looked at the number of days a
patient had a temperature ≥38.0°C and found that an increased number of days at a
pyrexic temperature was associated with an increase in the likelihood of poor prognosis.
The authors concluded that the amount of time at or above a pyrexic temperature may be
an independent predictor for outcome (Bao et al. 2014). Although our study found similar
results, that duration of time at an elevated temperature could be independently predictive
of outcome, this only occurred when temperatures were at least 0.5°C above the
commonly used threshold of 38.0°C.
In a 2008 American Heart Association consensus statement, an approach to
comparing mortality rates using physiologic markers of post-arrest injury commonly
found in PCAS was suggested; this approach classifies the early post-arrest period as 20
minutes post-ROSC to 6-12 hours post-ROSC, the intermediate period between 6-12
hours and 72 hours post-ROSC, and the recovery phase as after 72 hours post-ROSC
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(Neumar et al. 2008). When looking at the association between outcomes and timing of
onset of pyrexia in comatose patients (arguably those with the most severe PCAS),
patients had better outcomes in the “early phase”, 0-10 hours post-arrest, than in the
“intermediate phase”, 10.2-72 hours post-arrest. In the other groups of patients, the
worsening outcomes related to the “intermediate phase” was capped at 24.5 hours, with
better outcomes between 25.5-72 hours, which could speak to a potentially different
course of PCAS neurologic injury in comatose versus other patients. Additionally,
laboratory investigations have suggested that many PCAS pathophysiological processes
are worsened by pyrexia (Polderman 2008; Winters et al. 2013), which can intensify the
neurologic injury caused by the ischemic insult of SCA and contributes to poor outcomes
(Adrie et al. 2002; Badjatia 2009; Bernard et al. 2002; Deakin et al. 2010; Ginsberg et al.
1992; Greer et al. 2008; Hickey et al. 2003; Hypothermia after Cardiac Arrest Study
Group 2002; Langhelle et al. 2003; Neumar et al. 2015; Takasu et al. 2001; Takino and
Okada 1991; Zeiner et al. 2001). This finding was contrary to that of Gebhardt et al, who
found no association between timing of onset of pyrexia and outcomes, although their
study only looked at the first 48 hours post-arrest and included both patients who had
received TTM and those who did not (Gebhardt et al. 2013).
Clinically, if “lower” pyrexic temperatures (such as ≤38.5°C) are not particularly
harmful and even possibly helpful, investigation into the ideal temperature threshold for
treatment of pyrexia would be prudent. On the other hand, once a patient reaches an
“elevated” pyrexic temperature, this study suggests that the length of time a patient
experiences that temperature needs to be as short as possible; only a few hours at elevated
temperatures are required before the duration of pyrexia becomes predictive of poor
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outcomes. Moreover, the timing of temperature elevation may be a marker of continued
PCAS injury.
However, as this is a retrospective registry study, there is a need for further
prospective studies in this area. This would reduce the limitations of using predefined
data points and the potential risk of data entry errors or inconsistencies and information
bias (such as if the highest temperature was not recorded in the patient medical record,
which could result in misclassification). Additionally, there may be a relationship
between the timing of onset of temperature ≥38.7°C that this study was underpowered to
find. As a retrospective study, whether increased body temperature causes brain injury
directly or merely acts as a surrogate marker for more severely damaged patients (BroJeppesen et al. 2013; Winters et al. 2013) cannot be tested, although our findings are
consistent with a large body of mechanistic work. Use of only patients not treated with
TTM may present a non-representative sample of all cardiac arrest patients, although this
group was deliberately chosen to analyze temperature outside of TTM. Despite these
limitations, use of a registry allows for a heterogeneous patient population, leading to
greater external validity and generalizability.

CONCLUSION
In patients experiencing post-arrest pyrexia, higher pyrexic temperatures were
associated with worse outcomes. Longer duration of pyrexia was associated with worse
outcomes at higher temperatures and onset of pyrexia in the first 10 hours post-arrest was
associated with better outcomes, suggesting that avoidance of high temperatures and
pyrexia after 10 hours post-arrest might improve outcomes.
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TABLES
Table 1: Variables Explored for Registry Risk Standardization
Age
Location of arrest
Whether patient went to the
cardiac catheterization lab
Treatment with TTM
If patient was transferred
Duration of arrest

Sex
Etiology of arrest
Whether patient went to the
electrophysiology lab
Bystander CPR provided
If intra-arrest epinephrine given
Year of arrest

Race
Initial pulseless rhythm
Whether patient regained
consciousness shortly post-arrest
If arrest was witnessed
Cumulative dose of intra-arrest
epinephrine

Table 2. Patient Demographics Stratified by Maximum Temperature in TTM-treated
Patients

Age, years (mean±SD)
Race
White
Black
Other
Male
Witnessed
Cardiac Etiology of Arrest
Out-of-Hospital Arrest
Initial Rhythm
VF/VT
Asystole
PEA
Duration of Arrest (median
minutes)
Survival to Discharge
CPC 1-2 at Discharge

Maximum
Temperature
≥38.0°C (n=179)
56.0±16.0

Maximum
Temperature
<38.0°C (n=286)
60.4±16.4

p-value

81 (45.8)
84 (47.5)
12 (6.8)
107 (59.8)
118 (69.4)
116 (65.9)
149 (83.2)

157 (56.5)
108 (38.9)
13 (4.7)
164 (57.3)
195 (72.2)
184 (66.2)
234 (81.8)

0.076

68 (39.5)
35 (20.4)
69 (40.1)

102 (38.5)
61 (23.0)
102 (38.5)

ns

18 (IQR: 10, 33)
118 (41.3)
94 (33.0)

ns
0.024
ns

20 (IQR: 10, 29)
93 (52.0)
62 (34.8)

0.001

ns
ns
ns
ns
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Table 3. Relationship of Temperature to Outcomes in TTM-treated Patients
Survival

pvalue
A: Relationship of Maximum Temperature to Outcomes
All patients
0.25 (0.10-0.59)
0.002
OHCA patients
0.43 (0.21-0.88)
0.022
B: Relationship of Pyrexia (38.0oC) to Outcomes
All patients
1.54 (1.00-2.35)
Patients with maximum
1.46 (0.95-2.26)
temperature ≥37oC
OHCA patients
1.36 (0.85-2.18)
IHCA patients
5.58 (1.36-18.41)
C: Relationship of Duration to Outcomes (in hours)
Time 38.0oC
All patients
1.03 (0.99-1.07)
OHCA patients
1.03 (0.99-1.07)
o
Time 38.8 C
All patients
0.82 (0.72-0.93)
OHCA patients
0.80 (0.69-0.93)

Neurologic
Outcome

p-value

0.30 (0.10-0.84)
0.10 (0.03-0.42)

0.022
0.002

0.048
0.088

0.85 (0.52-1.40)
0.85 (0.51-1.41)

0.53
0.519

0.205
0.005

1.07 (0.63-1.81)
1.23 (0.45-3.39)

0.799
0.689

0.205
0.207

1.02 (0.98-1.07)
1.04 (0.98-1.10)

0.366
0.163

0.002
0.004

0.86 (0.75-1.00)
0.69 (0.54-0.89)

0.045
0.005

Table 4. Patient Demographics Stratified by Maximum Temperature in Patients Not
Treated with TTM
Age (median [IQR] years)
Race
White
Black
Other
Male
Witnessed
Cardiac Etiology of Arrest
Out-of-Hospital Arrest
Initial Rhythm
VF/VT
Asystole
PEA
Duration of Arrest (median
[IQR] minutes)
Regained Arousal Shortly
Post-Arrest
Survival to Discharge
CPC 1-2 at Discharge

Maximum Temperature
≥38°C (n=228)
64 (52, 72)

Maximum Temperature
<38°C (n=350)
66 (56, 75)

116 (53.5)
92 (42.4)
9 (4.2)
141 (61.8)
185 (93.0)
118 (54.6)
64 (28.1)

169 (51.5)
142 (43.3)
17 (5.2)
191 (54.6)
257 (90.2)
205 (61.9)
114 (32.6)

68 (31.3)
32 (14.8)
117 (53.9)

103 (32.0)
45 (14.0)
174 (54.0)

0.965

6 (2, 14)

0.012

220 (62.9)
219 (62.6)
186 (53.1)

0.001
0.860
0.823

8 (4, 17)
111 (48.7)
141 (61.8)
119 (52.2)

p-value
0.013

0.814
0.084
0.283
0.089
0.252
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Table 5. Relationship of Temperature to Outcomes in Patients Not Treated with TTM
Survival

pvalue
A: Relationship of Maximum Temperature to Outcomes
All patients
0.57 (0.39-0.83)
0.004
OHCA patients
0.36 (0.14-0.88)
0.025
Patients Remained Comatose 0.49 (0.27-0.90)
0.021
Post-Arrest
B: Relationship of Pyrexia (38.0oC) to Outcomes
All patients
1.43 (0.94-2.17)
Patients with maximum
1.46 (0.95-2.26)
o
temperature ≥37 C
IHCA patients
1.58 (0.99-2.53)
Patients Remained Comatose 2.03 (1.16-3.57)
Post-Arrest

Neurologic
Outcome

p-value

0.56 (0.37-0.85)
0.35 (0.12-1.01)
0.43 (0.22-0.85)

0.006
0.053
0.016

0.093
0.088

1.51 (1.00-2.26)
0.85 (0.51-1.41)

0.048
0.519

0.056
0.014

1.78 (1.11-2.83)
1.89 (1.05-3.41)

0.016
0.034

Table 6. Association of Duration of Pyrexia and Outcome in Patients Not Treated with
TTM
Time at or above 38.3°C
All Patients
OHCA Patients
IHCA Patients
Patients Regained Arousal
Shortly Post-Arrest
Patients Remained Comatose
Post-Arrest
Time at or above 38.7°C
All Patients
OHCA Patients
IHCA Patients
Patients Regained Arousal
Shortly Post-Arrest
Patients Remained Comatose
Post-Arrest
Time at or above 39.0°C
All Patients
OHCA Patients
IHCA Patients
Patients Regained Arousal
Shortly Post-Arrest
Patients Remained Comatose
Post-Arrest

Survival

p-value

CPC 1-2

p-value

0.99 (0.96-1.02)
0.88 (0.79-0.98)
0.99 (0.96-1.03)
0.93 (0.88-0.99)

0.458
0.024
0.594
0.019

0.98 (0.95-1.02)
0.88 (0.79-0.98)
0.99 (0.95-1.02)
0.94 (0.89-0.99)

0.313
0.017
0.427
0.021*

1.02 (0.97-1.07)

0.422

1.01 (0.97-1.05)

0.670

0.95 (0.90-1.00)
0.78 (0.66-0.92)
0.97 (0.92-1.02)
0.88 (0.80-0.96)

0.034
0.003
0.211
0.006

0.94 (0.89-0.99)
0.74 (0.60-0.92)
0.95 (0.90-1.00)
0.89 (0.82-0.97)

0.030
0.006
0.071
0.007

0.99 (0.92-1.06)

0.744

0.97 (0.91-1.04)

0.392

0.90 (0.84-0.97)
0.74 (0.60-0.90)
0.93 (0.86-1.00)
0.77 (0.65-0.91)

0.005
0.003
0.036
0.002

0.88 (0.81-0.97)
0.68 (0.52-0.90)
0.90 (0.83-0.98)
0.80 (0.69-0.93)

0.006
0.006
0.018
0.003

0.95 (0.88-1.04)

0.266

0.93 (0.85-1.02)

0.136
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Table 7. Thresholds of Time at Pyrexic Temperatures Predictive of Outcome in Patients
Not Treated with TTM
38.8°C
All patients
Survival Time Threshold
Survival AUC
CPC 1-2 Time Threshold
CPC AUC
OHCA patients
Survival Time Threshold
Survival AUC
CPC 1-2 Time Threshold
CPC AUC
IHCA patients
Survival Time Threshold
Survival AUC
CPC 1-2 Time Threshold
CPC AUC
Patients who gained arousal shortly post-arrest
Survival Time Threshold
Survival AUC
CPC 1-2 Time Threshold
CPC AUC

39.0°C

39.3°C

39.5°C

5 hours
0.70
5 hours
0.73
5 hours
0.78
5 hours
0.78

2.5 hours
0.93
2.5 hours
0.88
5 hours
0.73
6 hours
0.70
5 hours
0.82
5 hours
0.78

Table 8. Association of Timing of Onset of Pyrexia to Outcomes in Patients Not Treated
with TTM
Survival
All Patients
0.17-10.0
reference
10.2-24.5
0.23 (0.10-0.54)
25.5-70.4
1.11 (0.57-2.17)
OHCA Patients
0.17-10.0
reference
10.2-24.5
0.07 (0.01-0.62)
25.5-70.4
0.38 (0.04-3.87)
IHCA Patients
0.17-10.0
reference
10.2-24.5
0.56 (0.24-1.32)
25.5-70.4
0.64 (0.28-1.43)
Patients Regained Arousal Shortly Post-Arrest
0.17-10.0
reference
10.2-24.5
0.60 (0.21-1.73)
25.5-70.4
1.63 (0.54-4.97)
Patients Remained Comatose Post-Arrest
0.17-10.0
reference
10.2-24.5
0.25 (0.09-0.71)
25.5-70.4
0.28 (0.09-0.83)

p-value

CPC 1-2

p-value

0.001
0.758

Reference
0.29 (0.12-0.70)
1.47 (0.79-2.75)

0.006
0.225

0.017
0.410

Reference
0.29 (0.07-1.24)
0.98 (0.21-4.58)

0.094
0.979

0.187
0.276

Reference
0.41 (0.18-0.95)
0.78 (0.36-1.69)

0.037
0.524

0.342
0.389

Reference
0.59 (0.22-1.59)
2.79 (0.96-8.08)

0.298
0.059

0.010
0.022

Reference
0.24 (0.09-0.66)
0.24 (0.08-0.71)

0.006
0.009
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Table 9. Association of Patient Types with Outcomes in Patients Not Treated with TTM
All Patients
High temperature–short duration–early
onset
High temperature–short duration–middle
onset
High temperature–short duration–late
onset
High temperature–long duration–early
onset
High temperature–long duration–middle
onset
High temperature–long duration–late
onset
Low temperature–short duration–early
onset
Low temperature–short duration–middle
onset
Low temperature–short duration–late
onset
Low temperature–long duration–early
onset
Low temperature–long duration–middle
onset
Low temperature–long duration–late onset
Patients Remained Comatose Post-Arrest
High temperature–short duration–early
onset
High temperature–short duration–middle
onset
High temperature–short duration–late
onset
High temperature–long duration–early
onset
High temperature–long duration–middle
onset
High temperature–long duration–late
onset
Low temperature–short duration–early
onset
Low temperature–short duration–middle
onset
Low temperature–short duration–late
onset

Survival

pvalue

CPC 1-2

pvalue

0.75 (0.06-9.27)

0.823

0.33 (0.04-3.03)

0.329

0.25 (0.04-1.74)

0.161

0.33 (0.05-2.21)

0.255

0.25 (0.01-4.92)

0.362

0.33 (0.02-6.37)

0.466

0.43 (0.10-1.81)

0.248

0.24 (0.06-0.95)

0.041

0.15 (0.04-0.63)

0.009

0.10 (0.03-0.43)

0.002

0.30 (0.06-1.51)

0.144

0.19 (0.04-0.94)

0.041

REFERENCE

REFERENCE

0.40 (0.10-1.54)

0.184

0.24 (0.07-0.88)

0.031

0.55 (0.16-1.96)

0.359

0.55 (0.17-1.78)

0.318

1.00 (0.21-4.71)

0.99

1.00 (0.24-4.18)

0.999

0.28 (0.07-1.20)

0.087

0.30 (0.07-1.19)

0.086

0.50 (0.11-2.32)

0.376

0.67 (0.15-2.92)

0.590

n/a
0.06 (0.00-1.32)

n/a
0.074

n/a

0.06 (0.00-1.32)

0.074

n/a

0.22 (0.02-2.42)

0.217

0.08 (0.01-0.84)

0.036

0.07 (0.01-0.75)

0.027

0.03 (0.00-0.31)

0.004

0.07 (0.01-0.82)

0.035

0.02 (0.00-0.30)

0.006

REFERENCE

REFERENCE

0.10 (0.01-0.98)

0.049

0.05 (0.00-0.53)

0.013

0.11 (0.01-1.09)

0.060

0.05 (0.00-0.51)

0.012
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Low temperature–long duration–early
onset
Low temperature–long duration–middle
onset
Low temperature–long duration–late onset

0.44 (0.02-9.03)

0.598

0.44 (0.02-9.03)

0.598

0.09 (0.01-1.03)

0.053

0.09 (0.01-1.03)

0.053

0.09 (0.01-1.03)

0.053

0.09 (0.01-1.03)

0.053
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ILLUSTRATIONS
Figure 1. Comparison of ROC Curves between Registry and Administrative Data in All
Patients
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Figure 2. Bland Altman Plot of Agreement between Registry and Administrative Risk
Standardization Models in All Patients
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Figure 3. Calibration Plot for Registry Data in All Patients
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Figure 4. Calibration Plot for Administrative Data in All Patients
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Figure 5. Comparison of ROC Curves between Registry and Administrative Data in Outof-Hospital Cardiac Arrest
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Figure 6. Comparison of ROC Curves between Registry and Administrative Data in InHospital Cardiac Arrest
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Figure 7. Association between Maximum Temperature and Neurologic Outcome in
TTM-treated Patients. The data are presented as the marginal probability (with 95%
confidence interval) of a favorable outcome (defined as a Cerebral Performance Category
[CPC] score of 1-2 at hospital discharge) given maximum temperature, controlling for
initial rhythm, whether the arrest was witnessed, duration of arrest, age, duration of TTM
maintenance, and year of arrest.
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Figure 8. Association between Maximum Temperature, Timing of Pyrexia Onset, and
Neurologic Outcome in Patients Not Treated with TTM. The data are presented as the
marginal probability (with 95% confidence interval) of a favorable outcome (defined as a
Cerebral Performance Category [CPC] score of 1-2 at hospital discharge) given
maximum temperature and timing of pyrexia onset. Low temp = 38.0°C -39.0°C; high
temp=39.1°C-42.6°C; early onset=0.2-10.0 hours post-arrest; middle onset=10.2-24.5
hours post-arrest; late onset=24.5-70.4 hours post-arrest
Association of Maximum Temperature, Timing of Pyrexia Onset, and Neurologic Outcome
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APPENDIX
Appendix Table 1: Patient Demographics in Registry Data
Age (median)
Male
Race
White
Black
Other
Initial Rhythm
Asystole
PEA
VF/VT
Cardiac Etiology of Arrest
OHCA
Witnessed Arrest
Bystander CPR (OHCA only)
Epinephrine Given
Epinephrine Dose (median)
Duration of Arrest (median)*
ROSC achieved
TTM Performed*
Patient Regained Consciousness after ROSC*
Survival to Hospital Discharge
CPC at Hospital Discharge

Matched
N=2453
63 (51, 74)
1409 (57.8)

Not Matched
N=169
63 (51, 74)
97 (57.4)

967 (44.1)
1088 (49.6)
140 (6.4)

52 (31.1)
99 (59.3)
16 (9.6)

604 (26.2)
1129 (49.0)
571 (24.8)
899 (60.6)
1305 (53.7)
1066 (74.8)
144 (26.3)
1031 (83.5)
2 (0, 3)
11 (5, 26)
1532 (62.5)
473 (19.8)
356 (17.4)
633 (25.8)
486 (20.0)

40 (26.5)
59 (39.1)
52 (34.4)
124 (75.6)
125 (74.4)
136 (82.9)
28 (26.9)
118 (73.3)
1 (0, 3)
21 (10, 34)
169 (100.0)
133 (11.5)
35 (31.3)
73 (43.2)
65 (38.5)

p-value
0.668
0.915

0.003

0.017
<0.001
<0.001
0.022
0.899
0.001
0.049
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

*only calculated on patients with ROSC
Appendix Table 2: Administrative Data Elements Used in Risk Standardization Model
for All Patients
Atrial Fibrillation (427.31)
Anoxic Brain Damage (348.1)
Cardiac Panel (order)
Blood alcohol level taken
(order)
Emergency endotracheal
intubation (31500)
Right heart angiocardiogram
(88.52)
Any use of cistatracurium
(order)
Rheumatic heart failure
(398.91)
Compression of brain (348.4)
Secondary malignant neoplasm
of respiratory and digestive
systems (197)

Age
Any use of atropine (order)
Annuloplasty (35.33)
Pure hypercholesterolemia
(272)
Human immunodeficiency
virus [HIV] disease (42)
Malignant neoplasm of ovary
and other uterine adnexa (183)
Fiber-optic bronchoscopy
(33.22)
Obstructive sleep apnea
(327.23)
Cerebral edema (348.5)
Methicillin-resistant
Staphylococus aureus
septicemia (38.11)

Opioid dependence (304)
Blood culture (order)
CK (order)
150 mg of Amiodarone
(order)
Dissection of thoracic aorta
(441.01)
Respiratory failure (518.81,
518.83, 518.84, 799.1)
Toxic encephalopathy
(349.82)
Pneumococcal pneumonia
(481)
Urinary tract infection (599)
Acute venous embolism and
thrombosis of other specified
veins (453.8)
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Right heart cardiac
catheterization (37.21)
Tricuspid valve disease (397)
Cardiogenic shock (785.51)
Takotsubo syndrome (429.83)
Perforation of intestine (569.83)
Venous blood gas (order)
Chronic kidney disease stage V
(585.5)
Cellulitis of neck (682.1)
Persistent vegetative state
(780.03)
Bacteremia (790.7)
Insert endotracheal tube (96.04)
Insertion of drug-eluting
coronary artery stent(s) (36.07)
Malfunctioning prosthetic heart
valve (996.02)
Cardiology/Cardiovascular
Consultation (order)
1 mg of Epinephrine (order)
Hypoxemia (799.02)
Morbid obesity (278.01)
Urine culture (order)
Lymphoid leukemia (204)
Intestinal infection due to
clostridium difficile (8.45)
Hemiplegia (342.9)
Angioplasty or atherectomy of
other non-coronary vessel(s)
(39.5)
Open and other replacement of
aortic valve (35.22)
(Aorto)coronary bypass of two
coronary arteries (36.12)
Systemic inflammatory
response syndrome due to
noninfectious process without
acute organ dysfunction
(995.93)
Removal of lead(s) [electrode]
without replacement (37.77)
Extracorporeal circulation
auxiliary to open heart surgery
(39.61)
Coronary atherosclerosis of
native coronary artery (414.01)

Left heart cardiac
catheterization (37.22)
Food/vomit pneumonitis (507)
Hemopericardium (423)
Aortic atherosclerosis (440)
History of tobacco use
(V15.82)
Acute necrosis of liver (570)
Other intubation of respiratory
tract (96.05)
Drug dermatitis (693)
Measure blood oxygen level
(94760)
AICD check (89.49)
Sepsis (995.91)
Packed red blood cell use
(order)
Ventilator associated
pneumonia (997.31)
Cardiopulmonary resuscitation
(92950, 93.93, 99.60)
E. coli infection (41.4)
Race
Chest X-ray (order)
Chest X-ray (order)
CK-MB & Troponin (order)
Insertion Of Intercostal
Catheter For Drainage (34.04)
Atrioventricular block (426.1)
Acute or chronic combined
systolic and diastolic heart
failure (428.41, 428.43)
Critical illness myopathy
(359.81)
(Aorto)coronary bypass of
three coronary arteries (36.13)
Emergency department visit
for the evaluation and
management of a patient, high
complexity medical decision
making (99285)
Respiratory system disease
(519.8)
Acute myocardial infarction of
inferoposterior wall, initial
episode of care (410.31)
Chronic ischemic heart disease
(414.8)

Right/left heart cardiac
catheterization (37.23)
Bone marrow biopsy (41.31)
Long QT syndrome (426.82)
Pulmonary collapse (518)
Any use of nitroglycerin
(order)
Acute kidney failure (584.9)
Malfunctioning cardiac
pacemaker (996.01)
Coma (780.01)
Injection or infusion of
immunoglobulin (99.14)
Anaphylactic shock (995)
Atrial cardioversion (99.61)
Chronic kidney disease
(585.9)
Accidental poisoning –
psychstimulant (E85.42)
Do not resuscitate order
(V49.86, order)
Fresh frozen plasma (order)
Year of arrest
Arterial blood gas (order)
500 mg of Flagyl (order)
CK-MB Isoenzyme (order)
Dopamine 800 mg infusion
(order)
Liver transplant (50.59)
Open and other replacement
of aortic valve with tissue
graft (35.21)
Insertion of other
(naso)gastric tube (96.07)
Other gram negative bacteria
(41.85)
Initial insertion of
transvenous leads
[electrodes] into ventricle or
atrium and ventricle (37.71,
37.72)
Implantable heart assist
system (37.66)
Mobitz (type) II
atrioventricular block
(426.12)
Intermediate coronary
syndrome (411.1)
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Other diagnostic procedures on
heart and pericardium (37.29)

Enteral infusion of
Complications of
concentrated nutritional
transplanted bone marrow
substances (96.6)
(996.85)
Percutaneous [endoscopic]
Occlusion and stenosis of
Cerebral embolism with
gastrostomy [PEG] (43.11)
carotid artery (433.1)
cerebral infarction (434.11)
Acute venous embolism and
Chronic venous embolism and Chronic venous embolism
thrombosis of other specified
thrombosis of internal jugular and thrombosis of other
veins (453.84)
veins (453.76)
thoracic veins (453.77)
Local infection due to central
Other specified disorders of
Pulmonary artery wedge
venous catheter (999.33)
circulatory system (459.89)
monitoring (89.64)
Personal history of transient
Personal history of (corrected) Continuous invasive
ischemic attack (TIA), and
congenital malformations of
mechanical ventilation for 96
cerebral infarction without
heart and circulatory system
consecutive hours or more
residual deficits (V12.54)
(V13.65)
(96.72)
Pacemaker (414.06)
Sepsis (order)
Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites,
documentation of selected vessel patency, concurrent real-time ultrasound visualization of
vascular needle entry, with permanent recording and reporting (76937)
Any poisoning (963.0, 963.1, 964.2, 965.00, 965.02, 965.09, 965.8, 967.0, 967.8, 969.03, 969.3,
969.7, 969.72, 970.81, 971.2, 971.3, 972.6, E85.04, E85.1, E85.29, E85.42, E85.55, E85.56,
E85.82, E85.89, E868.9, E95.00, E95.01, E95.04, E980.2)
Implantation of cardiac resynchronization defibrillator or automatic cardioverter/ defibrillator,
total system (0.51, 37.94)

Appendix Table 3: Administrative Data Elements Used in Risk Standardization Model
for Out-of-Hospital Cardiac Arrest Patients
Atrial Fibrillation (427.31)
Spinal tap (3.31)
Delirium due to conditions
classified elsewhere (293)
Anoxic Brain Damage
(348.1)
Cardiogenic shock (785.51)
Bacteremia (790.7)
Fluid overload (276.69)
Intestinal infection due to
clostridium difficile (8.45)
Obesity (278)
Hemiplegia (342.9)
Other pulmonary embolism
and infarction (415.19)
Percutaneous [endoscopic]
gastrostomy [PEG] (43.11)
Acute myocardial infarction
of other inferior wall, initial
episode of care (410.41)
Coronary atherosclerosis of

Age
Any use of aspirin (order)
Ventilator associated
pneumonia (997.31)
Pure hypercholesterolemia
(272)
Cerebral edema (348.5)
Acidosis (276.2)
Sepsis (995.91)
Insertion of drug-eluting
coronary artery stent(s) (36.07)
Race
Any use of epinephrine (order)
Chronic ischemic heart disease
(414.8)
Insertion of non-drug-eluting
coronary artery stent(s) (36.06)
Insertion of temporary
transvenous pacemaker system
(37.78)
Acute myocardial infarction of

150 mg of Amiodarone (order)
Hyperpotassemia (276.7)
Cardiopulmonary resuscitation
(92950)
Insert endotracheal tube
(96.04)
Food/vomit pneumonitis (507)
Anaphylactic shock (995)
Fresh frozen plasma (order)
Do not resuscitate order
(V49.86, order)
Year of arrest
Hemodialysis (39.95)
Other gram negative bacteria
(41.85)
Implant of pulsation balloon
(37.61)
Video and radio-telemetered
electroencephalographic
monitoring (89.19)
Injection or infusion of other
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native coronary artery
(414.01)
Venous catheterization, not
elsewhere classified (38.93)
Other dependence on
machines, Appendix oxygen
(V46.2)
Septicemia (38.9)
Sinoatrial node dysfunction
(427.81)
Unspecified acute edema of
lung (518.4)
Old myocardial infarct (412)
Insertion of temporary
indwelling catheter, simple
(51702)

other anterior wall, initial
therapeutic or prophylactic
episode of care (410.11)
substance (99.2)
Interruption of the vena cava
Insertion of two vascular stents
(38.7)
(0.46)
Other complications due to
Other and unspecified
renal dialysis device, implant,
Escherichia coli [E. coli]
and graph (996.73)
(41.49)
Mitral valve disorder (424)
Ventricular fibrillation (427.41)
Chronic systolic heart failure
Acute on chronic systolic heart
(428.22)
failure (428.23)
Angiocardiography of left
Combined right and left heart
heart structures (88.53)
angiocardiography (88.54)
Packed cell transfusion (99.04) Foreign body in trachea (934)
Continuous invasive
Continuous invasive
mechanical ventilation for less mechanical ventilation for 96
than 96 consecutive hours
consecutive hours or more
(96.71)
(96.72)
Poisoning by cocaine
Arterial pressure monitor
Any use of nitroglycerin
(970.81)
(89.61)
(order)
Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites,
documentation of selected vessel patency, concurrent real-time ultrasound visualization of
vascular needle entry, with permanent recording and reporting (76937)
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode
recording, when performed, follow-up or limited study (93308)
Emergency department visit for the evaluation and management of a patient, high complexity
medical decision making (99285)

Appendix Table 4: Administrative Data Elements Used in Risk Standardization Model
for In-Hospital Cardiac Arrest Patients
Age
Right heart angiocardiogram
(88.52)
Takotsubo syndrome (429.83)
Compression of brain (348.4)
Secondary malignant
neoplasm of respiratory and
digestive systems (197)
Right heart cardiac
catheterization (37.21)
Fiber-optic bronchoscopy
(33.22)
Spinal tap (3.31)
Persistent vegetative state
(780.03)
AICD check (89.49)
Malfunctioning prosthetic
heart valve (996.02)

Acidosis (276.2)
Human immunodeficiency
virus [HIV] disease (42)
Annuloplasty (35.33)
Shock (785.5)
Angioplasty or atherectomy of
other non-coronary vessel(s)
(39.5)
Left heart cardiac
catheterization (37.22)
Food/vomit pneumonitis
(507)
Acute necrosis of liver (570)
CK-MB and troponin order in
the ER (order)
Drug dermatitis (693)
Ventilator associated
pneumonia (997.31)

Opioid dependence (304)
Acute and chronic respiratory
failure (518.84)
Urinary tract infection (599)
Long QT syndrome (426.82)
Initial insertion of transvenous
leads [electrodes] into ventricle
(37.71)
Chronic kidney disease stage V
(585.5)
Obstructive sleep apnea
(327.23)
Sepsis (995.91)
Do not resuscitate status
(V49.86)
Coma (780.01)
Subarachnoid hemorrhage
(852.05, 430)
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Perforation of intestine
(569.83)
Friedländer's bacillus
infection in conditions
classified elsewhere and of
unspecified site (041.3)
Hypoxemia (799.02)
Critical illness myopathy
(359.81)
Intestinal infection due to
clostridium difficile (8.45)
Hemiplegia (342.9)
(Aorto)coronary bypass of
two coronary arteries (36.12)
Extracorporeal circulation
auxiliary to open heart surgery
(39.61)
Acute venous embolism and
thrombosis of other specified
veins (453.84)
Chronic hepatitis C with
hepatic coma (070.44)
Infusion of a vasopressor
(0.17)
Noninvasive programmed
electrical stimulation [NIPS]
(37.20)
Candidiasis of lung (112.4)

Percutaneous [endoscopic]
gastrostomy [PEG] (43.11)
Implantation or replacement
of automatic cardioverter/
defibrillator, total system
(37.94)
Arterial blood gas (order)
Dependence on respirator,
status (V46.11)
Intermediate coronary
syndrome (411.1)
Severe sepsis (995.92)
(Aorto)coronary bypass of
three coronary arteries (36.13)
Chronic venous embolism and
thrombosis of internal jugular
veins (453.76)
Enteral infusion of
concentrated nutritional
substances (96.6)
Local infection due to central
venous catheter (999.33)
Open aortic valvuloplasty
(35.11)
Initial insertion of transvenous
leads [electrodes] into atrium
and ventricle (37.72)
Obesity (278)

Septicemia due to escherichia
coli [E. coli] (038.42)
Other pulmonary insufficiency,
not elsewhere classified
(518.82)
Year of arrest
Other respiratory complications
(997.39)
History of sudden cardiac
arrest (V12.53)
Liver transplant (50.59)
Other diagnostic procedures on
heart and pericardium (37.29)
Chronic venous embolism and
thrombosis of other thoracic
veins (453.77)
Pseudomonas infection in
conditions classified elsewhere
and of unspecified site (041.7)
Critical illness polyneuropathy
(357.82)
Hemiplegia/hemiparesis
(438.2)
Percutaneous transluminal
coronary angioplasty [PTCA]
(00.66)
Diagnostic ultrasound of heart
(88.72)
Interruption of the vena cava
(38.7)
Other specified alveolar and
parietoalveolar
pneumonopathies (516.8)
Other primary
cardiomyopathies (425.4)
Intracerebral hemorrhage (431)
Influenza with pneumonia
(487)
Retention of urine (788.2)
Chronic stomach ulcer with
hemorrhage (531.4)

Implant of pulsation balloon
Initial insertion of dual(37.61)
chamber device (37.83)
Occlusion and stenosis of
Central venous catheter
carotid artery with cerebral
placement with guidance
infarction (433.11)
(38.97)
Angiocardiography of venae
Other pulmonary embolism
cavae (88.51)
and infarction (415.19)
Respiratory arrest (799.1)
Systolic heart failure (428.2)
Other second degree
Pneumonia due to
atrioventricular block (426.13) Pseudomonas (482.1)
Osteoporosis (733)
Syncope and collapse (780.2)
Continuous invasive
Continuous invasive
mechanical ventilation for less mechanical ventilation for 96
than 96 consecutive hours
consecutive hours or more
(96.71)
(96.72)
Complete kidney transplant
Complete liver transplant
Complete lung transplant
(996.81)
(996.82)
(996.84)
Insertion of temporary non-implantable extracorporeal circulatory assist device (37.62)
Suicide and self-inflicted poisoning by other specified drugs and medicinal substances (E95.04)
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Appendix Table 5. Patient Types for Patients Treated with TTM
n
Low temperature – short duration – early timing
Low temperature – short duration – middle timing
Low temperature – short duration – late timing
Low temperature – long duration – early timing
Low temperature – long duration – middle timing
Low temperature – long duration – late timing
High temperature – short duration – early timing
High temperature – short duration – middle timing
High temperature – short duration – late timing
High temperature – long duration – early timing
High temperature – long duration – middle timing
High temperature – long duration – late timing

37
13
14
25
21
5
10
2
1
38
10
3

Maximum
temperature
(oC)
38.00-38.72
38.00-38.72
38.00-38.72
38.00-38.72
38.00-38.72
38.00-38.72
38.78-42.20
38.78-42.20
38.78-42.20
38.78-42.20
38.78-42.20
38.78-42.20

Duration
of Pyrexia
(hours)
0.40-9.15
0.40-9.15
0.40-9.15
9.75-60.75
9.75-60.75
9.75-60.75
0.40-9.15
0.40-9.15
0.40-9.15
9.75-60.75
9.75-60.75
9.75-60.75

Timing
(hours)
0.0-16.5
18.0-40.2
43.4-70.9
0.0-16.5
18.0-40.2
43.4-70.9
0.0-16.5
18.0-40.2
43.4-70.9
0.0-16.5
18.0-40.2
43.4-70.9

Appendix Table 6. Potential Covariates for Patients Treated with TTM
Sex
Intra-arrest
epinephrine given
Treating hospital
Location of arrest

Age
Cumulative dose of
intra-arrest epinephrine
Witnessed arrest
Initial pulseless rhythm

Year of arrest
Duration of TTM
maintenance
Bystander CPR
Length of hospital
stay

Race
Duration of TTM
rewarming
Duration of arrest
Time to TTM target
temperature
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Appendix Table 7. Characteristics of Patients by Timing of Onset of Pyrexia in Patients
Not Treated with TTM

Age (median [IQR] years)
Race
White
Black
Other
Male
Witnessed
Cardiac Etiology of Arrest
Out-of-Hospital Arrest
Initial Rhythm
VF/VT
Asystole
PEA
Duration of Arrest (median
[IQR] mins)
Regained Arousal Shortly
Post-Arrest
Survival to Discharge
CPC 1-2 at Discharge

“Early Onset”
(0.2-10.0 hours
post-arrest;
n=63)
61 [48, 71]

“Middle Onset”
(10.2-24.5
hours postarrest; n=70)
65 [56, 74]

“Late Onset”
(25.5-70.4
hours postarrest; n=73)
66 [55, 75]

34 (56.7)
22 (36.7)
4 (6.7)
40 (63.5)
47 (94.0)
32 (52.5)
11 (17.5)

32 (47.1)
32 (47.1)
4 (5.9)
42 (60.0)
59 (95.2)
37 (56.9)
27 (38.6)

40 (57.1)
30 (42.9)
0 (0.0)
48 (65.8)
62 (92.5)
35 (50.7)
19 (26.0)

22 (35.5)
10 (16.1)
30 (48.4)
7 [4, 16]

15 (22.7)
7 (10.6)
44 (66.7)
10 [4, 20]

25 (36.2)
11 (15.9)
33 (47.8)
8.5 [4, 16]

35 (55.6)

30 (42.9)

40 (54.8)

0.246

47 (74.6)
40 (63.5)

36 (51.4)
27 (38.6)

48 (65.8)
43 (58.9)

0.019
0.008

pvalue

0.127

0.140
0.773
0.924
0.762
0.023

0.187
0.387

Appendix Table 8. Patient Types for Patients Not Treated with TTM

Low temperature – short duration – early onset
Low temperature – short duration – middle onset
Low temperature – short duration – late onset
Low temperature – long duration – early onset
Low temperature – long duration – middle onset
Low temperature – long duration – late onset
High temperature – short duration – early onset
High temperature – short duration – middle onset
High temperature – short duration – late onset
High temperature – long duration – early onset
High temperature – long duration – middle onset
High temperature – long duration – late onset

n

Maximum
temperature
(°C)

20
26
45
20
17
15
4
6
2
19
21
11

38.0-39.0
38.0-39.0
38.0-39.0
38.0-39.0
38.0-39.0
38.0-39.0
39.1-42.6
39.1-42.6
39.1-42.6
39.1-42.6
39.1-42.6
39.1-42.6

Duration
of
Pyrexia
(h)
0.0-10.5
0.0-10.5
0.0-10.5
10.5-54.1
10.5-54.1
10.5-54.1
0.0-10.5
0.0-10.5
0.0-10.5
10.5-54.1
10.5-54.1
10.5-54.1

Timing
of Onset
(h)
0.17-10.0
10.2-24.5
25.5-70.4
0.17-10.0
10.2-24.5
25.5-70.4
0.17-10.0
10.2-24.5
25.5-70.4
0.17-10.0
10.2-24.5
25.5-70.4
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Appendix Figure 1. Bland Altman Plot of Agreement between Registry and
Administrative Risk Standardization Models in Out-of-Hospital Cardiac Arrest
Agreement between Registry and Administrative Risk Standardization:
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Appendix Figure 2. Bland Altman Plot of Agreement between Registry and
Administrative Risk Standardization Models in In-Hospital Cardiac Arrest
Agreement between Registry and Administrative Risk Standardization:
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